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ABSTRACT 
The aim of the project was to investigate the potential of 
ionic polysaccharide/drug complexes as controlled release drug 
delivery systems. 
Two highly purified alginates from Laminaria hyperborea and 
Ascophyllum nodosum were characterised in terms of molecular 
weight, polydispersity and M:G ratio using gel permeation 
chromatography (GPC), low-speed sedimentation in the analytical 
ultracentrifuge and GPC combined with multi-angle laser 
light-scattering. 
Viscometric and nephelometric studies provided evidence 
that, above certain concentrations of propranolol, there was an 
interaction between propranolol and alginate in deionised water 
resulting in the formation of an insoluble complex, which 
dissociated in the presence of counter-ions, for example, sodium 
chloride. 
Binding studies were undertaken using eqUilibrium dialysis in 
order to quantify this interaction in the presence and absence of 
sodium chloride. These indicated that there was a one-to-one 
stoichiometric relationship between propranolol and the carboxyl 
group on each uronic acid reSidue of the alginate and that negative 
co-operativity was occurring, such that the binding of one 
propranolol molecule to the alginate made it more difficult for 
subsequent propranolol molecules to bind. The possible in-vacuo 
three-dimensional structure of the molecular complex was modelled 
using computational molecular modelling techniques. 
A freeze-dried complex of propranolol and alginate was 
prepared and characterised. In vitro investigations indicated that 
drug release from the complex (formulated as a suspension in 
deionised water or in isotonic glycerol solution) was delayed 
compared with release from a propranolol solution. 
The release of propranolol from the propranolol/ alginate 
complex was assessed in vivo using the anaesthetised rat as an 
animal model for nasal delivery. It was found that the rate of 
absorption of propranolol from the complex was much slower and 
was sustained over a greater period of time, compared with 
absorption from a propranolol solution. In addition, the 
bioavailability of the drug from the complex was comparable to that 
of the solution and to that of an intravenous dose carried out in rats 
by other workers (Hussain et al 1980b). 
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CHAPTER 1 INTRODUCTION 
1.1 ALGINATES - GENERAL 
1.1.1 Introduction 
The alginates are naturally occurring polysaccharides which 
comprise alginic acid and its salts. Alginic acid was first discovered 
by the British chemist E.C.C. Stanford around 1880 (Stanford 1881). 
It is present in all species of the brown seaweed or Phaeophycae 
(Cottrell and Kovacs 1977), and to a lesser extent in some species of 
the Corallinacae or red algae (Okazaki et al 1982). A type of alginate 
has also been discovered in the extracellular mucilage of certain 
bacteria (Linker and Jones 1964, Gorin and Spencer 1966), for 
example Azotobacter vinelandii, and several species of Pseudomonas 
(Govan et al 1981, Linker and Jones 1966), although, at present, 
this is not used as an industrial source of the material. 
In the Phaeophycae, alginates are thought to have a skeletal 
function, giving strength, shape and flexibility to the plants. The 
Phaeophycae include the species Laminaria (present along the 
coasts of Britain, Norway, France, North America, and Japan), 
AscophyUum (Britain), and Macrocystis (U.S.A.). These abundant 
supplies are regularly harvested for the commercial production of 
alginates. 
1.1.2 Commercial Processina 
The alginate content of a seaweed can vary from 100/0 to 470/0 
from one species to another and also between different parts of the 
same plant (PerCival 1970). 
In the brown seaweeds, alginate is usually present as the 
insoluble mixed salt (sodium, potaSSium, magneSium, calcium and 
sometimes strontium and barium) of alginic acid. The basiC aim of 
-1-
commercial processing is to convert this naturally occurring mixed 
salt of alginic acid into a soluble salt, for example, sodium alginate, 
which is relatively free from impurities. 
In the commercial method of extraction (illustrated in Figure 
1.1), seaweed is washed, then digested with alkali to dissolve the 
alginate, and flltered to remove insoluble material. Calcium chlOride 
is added to the filtered solution to cause precipitation of calcium 
alginate. This is then aCidified to precipitate alginic acid, which can 
then be converted to the desired salt by treating with the 
appropriate carbonate, oxide or hydrOxide, and finally dried. 
1.1.3 Structure 
Originally, alginate was thought to be homopolymeric and to 
be composed of D-mannuronic acid (Nelson and Cretcher 1930). 
However, Fischer and Dorfel (1955), showed that hydrolysed 
fractions of laboratory-produced and commercial alginates contained 
L-guluronic acid as well as D-mannuronic acid. It is now well known 
that except for certain bacterial 'alginates' (Skjeik-Brrek et al 1986), 
alginates contain both L-guluronic acid and D-mannuronic acid. 
In fact, algal alginates are linear block co-polymers of 
(l-4)-linked ~ - D - m a n n u r o n i c c acid (M) (Figure 1.2), and 
a-L-guluronic acid (G) (Figure 1.3) residues, in various proportions 
depending on the source (Haug and Larsen 1962). Studies have 
shown that the M and G residues are not arranged in a completely 
random manner, but that the monomers are arranged within the 
alginate molecule as a series of block structures (Haug et al 1967a). 
These blocks may be homopolymeric, that is, blocks of repeating 
D-mannuronic acid (M-blocks) or L-guluronic acid (G-blocks), or 
may be heteropolymeric, that is, blocks where the two acids 
alternate (MG-blocks). 
Methods used to determine block structure in alginates have 
-2-
Figure 1. 1 Commercial Processing of Alginates 
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Figure 1.2 The structure of ~ - D - m a n n u r o n i c c acid 
(4C 1 conformation) 
HO 
OH 
Figure 1.3 The structure of a-L-guluronic acid 
(lC4 conformation) 
OH 
HO 
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included: (1) IR spectroscopy (Mackie 1971); (ti) PMR spectroscopy 
following hydrolysis (Penman and Sanderson 1972); (iii) 13C-NMR 
spectroscopy after enzymic hydrolysis (Boyd and Turvey 1978). and 
after mild acid hydrolysis (Grasdalen et al 1977. 1981); {iv) circular 
dichrOism (Morris et al 1975); (v) IH NMR (Grasdalen et al 1979). 
These and other investigations have demonstrated that 
alginates do not have any regular repeating copolymer structure 
(Painter et al 1968. Larsen et al 1970. Smidsr0d and Whittington 
1969). However, the most frequent structure within the alginate is 
blocks of M and blocks of G, connected by blocks of mixed M and G, 
of predominantly alternating structure. 
1.1.4 Gelation Properties 
In the presence of certain divalent and multivalent cations. 
for example Ca2+, alginates form gels. The properties of these gels 
depends upon the mannuronic acid to guluronic acid ratio (M:G 
ratio) of the alginate. Alginates with a high guluronic acid content 
form strong brittle gels, whereas those with a high mannuronic acid 
content form weaker but more flexible gels. (Smidsr0d and Haug 
1972b, Penman and Sanderson 1972). 
There are only minor differences in the structure of the two 
monomers and their affinity for divalent cations, thus the large 
difference seen in ion-binding by poly-guluronate and 
poly-mannuronate groups must have a macromolecular explanation: 
In order that the bulky carboxyl group is in the energetically 
favoured equatorial pOSition, the two uronic acids will adopt 
different preferred conformations. Thus, mannuronic acid adopts 
the 4C 1 chair conformation (Figure l.2). and guluronic acid adopts 
the lC4 boat form (Figure l.3). Evidence from X-ray diffraction 
studies supports this theory (Atkins et al 1971). 
The orientation of the glycosidic bonds between the 
monomers will then affect the conformation of the polysaccharide 
-5-
chain. Therefore, it has been predicted (Rees 1972), that regions in 
which poly-D- mannuronate predominates (M-M-M) will form an 
extended ribbon structure (Figure 1.4), similar to that of cellulose. 
whereas regions in which poly-L-guluronate predominates (G-G-G) 
will form a buckled chain (Figure 1.5). Further X-ray diffraction 
experiments by Atkins et al (l973a and 1973b), together with 
solution studies using 1H-NMR (Penman and Sanderson 1972), and 
13C-NMR (Grasdalen et al 1977) provide evidence to confirm this 
prediction. 
The mode of binding of cations by the various block 
structures within the alginate explains why the gels formed have 
different properties depending on the ratio of D-mannuronate to 
L-guluronate (M:G ratio). All the block structures are polyanionic and 
will form intermolecular bonds with divalent or multivalent cations, 
such as Ca2+. However, poly-guluronate regions are also able to 
chelate the metal ion because of the spatial arrangement of the ring 
and hydroxyl oxygen atoms, thereby forming a much stronger type of 
interaction. Cavity-like sites are formed between adjacent G-units 
into which ions such as Ca2+ fit well (Figure 1.6). Thus, two or more 
chains may be joined together, side by side, by salt bridge formation 
between the G-blocks. This has been likened to the cross-section of 
an 'egg-box' (Grant et al 1973) as shown in Figure 1.7, where the 
Ca2+ ions are the 'eggs' within the 'egg-box'-like cross section of the 
alginate chains. 
For this reason, when controlled amounts of calcium are 
added to alginate solutions, gels are formed. The calCium ions bind 
strongly to the G-blocks, but the formation of an insoluble 
precipitate is prevented by the presence of the M -blocks and the 
MG-blocks where the interaction with calCium ions is less. Since 
most alginates contain all three types of block structure (M, G, and 
MG), a classical gel structure can be formed where the G-blocks 
form the junction zones which are terminated by regions of 
M-blocks or MG-blocks. These remain dissolved and keep the 
-6-
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Figure 1.4 Chain confonnation of p o l y - ~ - D - m a n n u r o n a t e e
('extended ribbon') 
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Figure 1.5 Chain confonnation of poly-a-L-guluronate 
('buckled chain') 
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system in solution as a hydrated three-dimensional network. thereby 
forming a gel. 
As already mentioned. alginate is generally believed to have a 
skeletal function in the brown algae. The M:G ratio of the alginate in 
different algae or in different tissues of the same algal plant reflects 
the relationship between alginate structure and its required 
function. For example. in Laminaria h y p e r b o r e ~ ~ which grows in 
exposed coastal regions. the holdfast and stipe have a high guluronic 
acid content. giving strength and rigidity to these parts of the plant. 
whereas the blades. which float in the water. have a lower guluronic 
acid content. making them more flexible. 
1.1.5 Toxicolon 
Many toxicological studies on alginates have been carried out. 
These have mainly taken the form of feeding trials. and have been 
summarised by McNeely and Kovacs (1975). They indicate that 
alginates are poorly absorbed by humans and that their consumption 
causes no significant harmful effects. Sodium alginate and propylene 
glycol alginate can be partially digested by coloniC bacteria and 
thereby form part of the carbohydrate of the diet. However, the 
greater part remains undigested. and if eaten in suffiCient 
quantities. may act as a bulk laxative (Berger et al 1953). 
Alginates are natural products. and therefore contain 
impurities such as heavy metals. pyrogens and immunogenic 
materials. for example. proteins. complex carbohydrates and 
nucleotides (Paoletti et al 1987). The most common contaminants of 
alginates are phenolic compounds. which cause discolouration and 
catalyse oxidative-reductive-depolymerisation resulting in a decrease 
in the viscosity of the alginate. 
For many applications of alginates, it is desirable that the 
above contaminants are removed. and this becomes a necessary 
requirement in applications such as transplantation (see section 
1.2.2). All commercially aVailable alginates are pretreated with 
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formaldehyde which coverts the phenols into insoluble phenol-
formaldehyde resin, but small amounts of phenolic compounds 
persist in all but the most highly purified. 
1.1.6 Physical Properties 
1.1.6.1 Stability 
The stability of alginates in the solid state at moderate 
temperatures (less than 250 C) is excellent, but tends to decrease 
with increasing temperatures. For example, a sodium alginate with a 
degree of polymerisation of approximately 500, may be stored at 
100C to 200C for three years with no observable change (McDowell 
1977). If the alginate is more highly polymerised, hydrolytic 
degradation may occur to form alginates of lower molecular weight, 
and this becomes more serious at higher temperatures (above 500 C). 
Alginates are hydrophilic colloids and will absorb mOisture from the 
atmosphere. The rate of depolymerisation increases in the presence 
of moisture, therefore they should be stored under cool, dry 
conditions. 
1.1.6.2. Solubility 
Alginic acid is virtually insoluble in cold water and only 
slightly soluble in hot water. This is because it is present largely in a 
crystalline state, giving it a very regular structure, in which there is 
ample opportunity for hydrogen bonding between the polymer 
chains. Therefore. the energy required to separate the molecular 
chains (the first step towards solution) is relatively high. 
The presence of acid groups on each hexose unit of the 
alginic acid molecule means that it may be easily brought into 
solution by the formation of an ionised monovalent salt. For this 
reason, the salts of the alkali metals and ammonia are soluble in 
water. However. the salts of most of the divalent and polyvalent 
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metals have only limited solubility. For example, as discussed 
previously, calcium interacts with alginates to form the 'egg-box' 
structure (Grant et al 1973) illustrated in Figure 1.7. This is a stable 
structure. which holds together to form a gel in the presence of 
water. The larger strontium ion is more firmly bound than calCium 
ions thus the salt is insoluble in water, but the small magneSium ion 
is not able to stabilise the structure in the same way, so that 
magneSium alginate is soluble in water. 
1.1.7 Solution Properties 
1.1.7.1 Viscosity 
The viscosity of alginate solutions is important for both 
theoretical and practical reasons. For example, the viscosity of 
extremely dilute solutions provides useful information about the size 
and shape of the alginate molecules. In many practical applications, 
such as when alginate is used at much higher concentrations as a 
thickening or suspending agent, it is the viscosity of the alginate 
solution which is critical. 
Measurements of viscosity of most alginates are carried out in 
very dilute solutions. so that the interaction between the alginate 
molecules and the solvent can be studied. and complications arising 
from interactions between individual alginate molecules are 
minimised. These measurements are often expressed as the 
'relative viscosity' or 11rel' which is the ratio of the viscosity of the 
solution 11 to the viscosity of the pure solvent 110 at the same 
temperature. Another useful expression is the 'specific viscosity', 
llsp which is defined as: 
11sp = llrel - 1. 
If the specific viscosity is divided by the concentration and a 
plot of Tlspl c versus c is extrapolated to zero concentration, this 
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ratio is known as the 'intrinsic viscosity' or [11]. which is a measure of 
the volume and shape of the space occupied by the molecules in 
solution (Florence and Attwood 1985). 
The viscosity of alginate solutions depends mainly upon 
temperature. concentration, molecular weight of the algInate. pH. 
and the presence of monovalent and polyvalent cations. Each of 
these will be discussed briefly. 
It is usual for any statement of viscosity to be accompanied by 
the temperature at which the measurement was made. because the 
viscosity of alginate solutions decreases with increasing 
temperature. This decrease is reversible provided that high solution 
temperatures are not maintained for long periods. Prolonged 
excessive temperatures lead to partial depolymerisation of the 
molecules. which results in a decrease in viscosity. 
As the concentration of an alginate solution is increased. the 
viscosity increases almost exponentially. This is a result of 
entanglement and interaction between the alginate molecules which 
restricts the flow of the solution. 
The relationship between the molecular weight and the 
viscosity of an alginate is more complex. Viscosity is determined 
largely by the length of molecules in solution. and thus molecules 
which are rigid in solution produce a higher viscosity than more 
flexible molecules of the same molecular weight. In general. 
alginates tend to be quite rigid molecules compared to other 
polysaccharides. and it has been found that this 'stiffness' is greatest 
in the G-blocks, followed by the M-blocks and lastly the MG-blocks 
(Smidsr0d et al 1973). Alginates are also polydisperse materials, and 
the uncertainty about molecular weight distribution means that the 
relationship between the intrinsic viscosity of an alginate solution 
and its mean molecular weight can only be expressed as an 
approximation. 
The pH of solution will also affect the viSCOSity. although 
between pH 5-10 the viscosity of alginate solutions is essentially 
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constant. Below pH 4.5 a significant viscosity increase occurs, due to 
the lower solubility of alginic acid, and below pH 3, insoluble alginic 
acid is precipitated. At a pH above 11.5, sodium alginates fonn gels. 
This is due to maximum ionisation of the alginate chains, resulting 
in mutual charge repulsion and a subsequent increase in the 
viscosity resulting in gel fonnation. 
Polyvalent metal ions increase the viscosity of soluble alginate 
salts, and, as already mentioned, will cause gelation and/or 
precipitation if present in suffiCient concentration. Small 
monovalent ions may cause a decrease in viscosity due to a reduction 
in charge on the alginate molecules resulting in their contraction in 
the solution. 
1.1.7.2 Fibn-form.tne ability 
Alginates possess excellent fllm-fonning properties, and a 
wide range of soluble and insoluble films can be prepared. Soluble 
films can be fonned by thin-layer drying of a solution. Extrusion of a 
soluble alginate into a precipitating solution (for example an acidic 
solution or a divalent or trivalent metal ion solution) produces an 
insoluble film. The films produced are tough, clear, flexible and 
resistant to grease, fats, oils and organic solvents, though they will 
transmit water vapour. When dry, the films are brittle, but they 
absorb moisture when in contact with normal atmospheres and 
become softer and more flexible. The fllm-fonnmg effect of alginates 
is suffiCient to hold together particles which have been wetted with 
an alginate solution and then dried. The alginate gradually 
decomposes on heating so that it is useful as a temporary binder in 
materials which must be fired, for example, ceramic glazes. The 
applications of alginates will be discussed further in the next 
section. 
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1.2. APPLICATIONS OF ALGINATES 
1.2.1 General Applications 
Alginates have an extremely wide range of applications which 
are intimately related to their basic physicochemical properties, and 
as already described, their lack of toxicity and relative stability at 
moderate temperatures. They produce viscous solutions at low 
concentrations, form soluble and insoluble films, and also form gels 
with many multivalent ions, especially calCium ions. These properties, 
together with their excellent stabilising and suspending properties 
have ensured that alginates have been extenSively used in the food and 
drinks industry. 
Alginic acid itself is relatively insoluble in water, therefore the 
most widely used compounds are the soluble salt sodium alginate, or 
the ester propylene glycol alginate. 
The uses of alginates in the food industry have been widely 
reviewed (McDowell 1960, Glicksman 1969). They have been used in 
the food and drinks industry as thickening, suspending, stabiliSing, 
emUlsifying, gel-producing and film-forming agents, which have the 
added advantage that they do not inhibit or mask flavours. A brief 
summary of the applications of certain alginates in the food industry is 
provided in Table 1.1. 
Alginates are also used for a variety of purposes in industry. 
They have a wide range of applications in the textile, welding and 
paper industries. Table 1.2 outlines some of these applications. 
A future application of alginates is in agriculture and forestry. 
At present, the widespread use of herbicides and other 
pest -controlling chemicals has led to the excessive introduction of 
toxic substances into the environment. pfister et al (1986) 
investigated calcium alginate gel formulations for the controlled 
release of herbiCides, and found that release of the herbicides could 
be maintained over several months, thereby reducing the need for 
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Table 1.1 Some Applications of Aleumtes in the Food Industry 
Property of 
AJ.elnate 
Gelation 
Emulsifying 
Stabilising 
Water-holding 
Food Product 
Dessert gels 
Pie fulings 
Salad dressings 
Meat and flavour 
sauces 
Beer 
Sauces and gravies 
Dry mixes 
Syrups 
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Application of 
AJeinate 
Produces clear. finn. 
quick-setting gels with hot 
or cold water. 
Develops soft gel body with 
broad temperature 
tolerance. 
EmulSifies. stabilises and 
modifies flow properties in 
pourable dressings. 
EmulSifies oils and 
suspends solids. 
Maintains beer foam under 
adverse conditions. 
Thickens and stabilises. 
Absorbs water or milk 
quickly upon 
reconstitution. 
Suspends solids, controls 
pouring consistency. 
provides body. 
Table 1.2 Some Industrial Applications of ~ t e s s
Property of 
Ale;lnate 
Water-holding 
Gelling 
Emulsifying 
Binding 
Product 
Adhesives 
Air freshener gel 
Toys 
Polishes 
Ceramics 
Paper sizing 
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Application of 
Ale;lnate 
Controls penetration to 
improve adhesion and 
application. 
Firm stable gels are 
produced. 
Safe, non-toxic materials 
are made for putty-like 
modelling materials. 
Emulsifies oils and 
suspends solids. 
Imparts plasticity and 
suspends solids. 
Improves surface 
properties, ink acceptance 
and smoothness. 
repeated applications of excess volumes of chemicals. This, together 
with the fact that the polymer matrix is biodegradable means that the 
replacement of conventional pesticide formulations with controlled 
release systems could have great advantages both ecologically and 
economically. 
1.2.2 Pharmaceutical and Medical Applications 
In the pharmaceutical industry, alginates are used not only as 
clinically active materials, for example in wound dressings (section 
1.2.2.2), but also as excipients in many drug formulations. 
As excipients, alginates may be used, for example, as swelling 
agents, stabilisers and suspending agents. The great variety of 
alginates commercially available means that important factors such as 
viscosity and thermostability may be selected for each individual 
product. 
In the past, alginates were a popular chOice as disintegrants in 
tablet production, since alginic acid swells in contact with water 
without dissolving. However, they have largely been replaced by the 
semi-synthetic starch and cellulose derivatives which provide 
improved control of disintegration. 
The film-forming properties of alginates are exploited in their 
use as enteric coats for tablets, since the fums are insoluble in the 
presence of acid, but dissolve rapidly in the alkaline conditions of the 
lower gastrOintestinal tract to effect drug release. 
This insolubility in acid also means that alginate is an effective 
anti-ulcer agent as it forms a protective film on the stomach lining. It 
has buffering capacities which make it useful as an antacid in the 
treatment of dyspepsia and gastric reflux. Pharmaceutical 
preparations on the market at present which contain alginates 
include 'Gaviscon', 'Gastrocote', 'Algicon', 'Gastron' and 'Topal', which 
are aVailable in tablet and/or liqUid form. 
'Gaviscon' contains alginate and a carbonate or bicarbonate, 
which releases carbon dioxide gas on contact with gastric acid. 
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Bubbles of gas become entrapped in the alginate gel network, which 
consequently floats on the stomach contents as a viscous layer. 1\vo 
possible modes of action have been suggested (Washington et al 
1986). Firstly, a physical barrier or 'raft' is formed on top of the 
stomach contents, thereby preventing contact of stomach acid with 
the sensitive epithelium of the oesophagus. As a secondary 
mechanism, if the raft is ruptured, only neutral raft material is 
refluxed into the oesophagus instead of the acidic gastric contents 
which usually cause the symptoms of 'heartburn'. 
Sodium alginate tablets have been administered in nuclear 
accidents in order to bind radioactive strontium which may be 
ingested with food (Einig and Knoll 1991). An insoluble salt is formed 
(section l.l.6.2) which is then excreted. 
Another useful application of alginates is that entrapment of 
living cells (for example, from bacteria, yeasts, plants and animals) in 
calcium alginate gels or in microcapsules of certain alginate salts can 
be achieved under mild conditions which cause no damage to the 
cells. It has been suggested that alginate gels containing pancreas 
cells could be used for the transplantation of insulin-producing tissue, 
possibly without an immune response (Skjak-Brrek et al 1989), and 
this will obviously have important consequences for future medical 
research into implantation and transplantation. 
In dentistry, alginates are used extensively as impression 
materials and dental adhesives. In a recent patent, Keith (1990) has 
deSCribed a further use for alginates in dentistry. Alginate was 
combined with chlorhexidine, a divalent cationic antiseptic, to form a 
precipitate. The author suggests that the powdered preCipitate is 
suitable for inclusion in a professional dentifrice or in a consumer 
toothpaste, and has the advantage that it avoids the bad taste and 
staining of tooth enamel that are normally a problem with 
chlorhexidine-containing formulations. 
1.2.2.1 Aients for Controlled Release of Drues 
As well as their traditional role in the pharmaceutical industry 
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as described above, alginates, together with other natural and 
synthetic polymers, are now being exploited for their use as agents to 
provide controlled delivery of drugs, and have applications in most 
routes of administration. For example, sustained oral drug delivery 
can be achieved by incorporating drug into a hydrophilic matrix tablet 
or into a gel fonnulation. Transdennal drug delivery and depot 
injections can be controlled by the chOice of a suitable polymer. Also, 
the potential use of alginates as implantation materials has been 
mentioned above. 
The use of alginates and other polysaccharides in hydrophilic 
matrix tablets is well documented (Melia 1991). At a simple level, a 
hydrophilic matrix system consists of a compressed mix of a drug 
with a viscous polymer which swells in water. In practice, many other 
excipients are added to improve the properties of the tablet. When 
the tablet comes into contact with body flUids, a thin gel fonns on its 
surface from which the active drug is released by a combination of 
diffusion through the gel and erosion of the gel surface. The tablet 
core stays dry and provides a reservoir both of active drug and of 
polymer to replace the gel layer as it is dissolved and eroded in the 
gastrointestinal tract. A very successful hydrophilic matrix system 
containing alginate and verapamil has become one of the best selling 
antihypertensive drugs worldwide (Einig and Knoll 1991). 
Alginate gels have also been studied as oral drug delivery 
systems. For example, Stockwell and Davis (1986) fonnulated gels 
containing sodium alginate, calcium ions, sodium bicarbonate, and a 
drug, resulting in a floating gel system as described for 'Gaviscon' in 
section 1.2.2. Sustained release was achieved for the anionic drug 
sodium salicylate, and to a greater extent for the cationic drug 
chlorpheniramine maleate, an effect suggested to be a result of 
electrostatic interactions between the positively-charged drug and 
the negatively-charged alginate. 
Calcium alginate beads have also been investigated for 
controlled release of drugs. The use of alginates to immobilise living 
cells has been discussed in section 1.2.2. This research led to studies 
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investigating the use of calcium alginate beads as a sustained release 
dosage form. Preparation of the beads is relatively Simple. As a general 
method, a sodium alginate solution is prepared, into which drug is 
dispersed. This is then forced drop by drop through capillary tubing 
into calcium chloride solution, where insoluble calCium alginate beads 
are formed. These are washed and then dried at room temperature. 
For example, Badwan and co-workers (1985) prepared alginate beads 
impregnated with sulphamethoxazole and reported sustained release 
of the drug. Bodmeier and Paeratakul (1988) formed alginate beads 
using poorly soluble drugs such as ibuprofen, indomethacin and 
tolbutamide, which reportedly did not diSintegrate in acidic 
conditions, but released drug in intestinal fluids. 
1.2.2.2 Wound Man8iement 
Alginates have gained great importance in the field of wound 
management. In 1962, it was observed by Winter that epithelisation of 
wounds beneath polythene films progressed at approximately twice 
the rate occurring under a dry scab (Winter 1962). This led to the 
philosophy of 'moist wound healing'. However, the occlusion of 
wounds with films was not immediately employed in wound 
management, due to the tendency for bacterial growth below the 
films. 
The development of materials such as 'Op-Site' (almost ten 
years later) which allowed the diffusion of air and water vapour which 
seemed to inhibit bacterial growth, led to the widespread use of film 
dressings. These original films had the disadvantage that, although 
they retained wound exudate in contact with the wound. thereby 
promoting moist healing, the exudate eventually became difficult to 
contain. Thus, hydrophilic foams. hydrogels and hydrocolloids which 
could absorb the exudate without affecting wound healing were 
developed. 
Originally, two products based on calcium alginate fibre were 
launched: 'Sorbsan' and 'Kaltostat'. Since then. these products have 
-20-
been developed further, and 'Sorbsan SA' and 'Kaltoclude' are now 
aVailable. According to the British National Formulary (1992), these 
products act as 'occlusive or semi-occlusive dressings which adhere 
to dry skin and interact with moisture in the wound to form a gel'. 
They are employed as treatments for exuding lesions, for example, 
pressure sores, burns and graft-donor sites. 
Another wound product based on alginate is 'Stop Hemo' 
which, as its name suggests, is used to arrest bleeding. When 
employed as a haemostatic agent, sodium alginate interacts with blood 
calCium to form cross-linked calCium alginate which seals the lesions 
and stops bleeding. It has been shown that alginate dressings can 
eliminate the need for blood transfUSions follOwing blood loss in 
certain types of surgery (Blair et al 1990). 
As wound healing agents, alginate dressings are used in 
preference to traditional products based on cotton, lint or gauze 
because they can be easily changed with no discomfort to the patient 
and relatively little damage to the wound itself. This is because, in 
use, the calCium alginate fibres slowly release calcium ions in 
exchange for sodium ions from the wound exudate, which liquefies 
the fibres. Therefore, dressings may be left in place for up to seven 
days, but, at any stage, washing with a sterile saline solution will 
liquefy and dissolve the dressing and with it the absorbed wound 
exudate. 
1.3 INTERACTIONS OF ALGINATES 
1.3.1 General 
Hydrocolloids such as alginates are long chain, high molecular 
weight polymers which dissolve or disperse in water (Burger 1982), 
and are often used to increase the viscosity of the medium in which 
they are dissolved. However, the behaviour of a hydrocolloid molecule 
in aqueous solution depends upon the interactions which occur 
between: 
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(a) hydrocolloid and solvent molecules; 
(b) individual hydrocollOid molecules: 
(c) hydrocolloid and other solute molecules in the system. 
Also, there may be indirect effects, for example, competition 
between hydrocollOid and other solute molecules for available water 
molecules, thereby changing the degree of hydration of the 
hydrocolloid. 
In very dilute solutions. the hydrocollOid-solvent interactions 
tend to be maximised and the intermolecular hydrocolloid-
hydrocolloid interactions are minimised, resulting in maximum 
extension of the hydrocollOid molecule and therefore a high 
intrinsic viscosity (section l.l.7.1). Increasing the concentration of 
hydrocollOid may lead to intermolecular interactions where the 
polymer coils begin to overlap (Mitchell 1979). A phenomenon 
known as 'entanglement coupling' occurs in concentrated solutions. 
such that the solution behaves like a crosslinked network (where 
the crosslinks have short lifetimes), thereby causing a marked 
increase in the viscosity of the solution (section l.l. 7.1). 
Hydrophilic polysaccharide polymers may be classified into 
non-ionic types (for example, cellulose ethers) or ionic types (for 
example. alginates, carrageenans and xanthan gum) which have 
carboxyl or sulphate side groups on the polysaccharide chains. 
Intennolecular interactions of polyanionic hydrocolloids. such as 
sodium alginate. may show differences compared with 
intennolecular interactions of non-ionic hydrocolloids. For example, 
the presence of charge on the molecule may either inhibit or 
promote intermolecular interactions. In addition. cations, whether 
unintentionally present or deliberately introduced, may have a 
specific role in the formation of intermolecular interactions. for 
example, as in the 'egg-box' model for the gelation of alginates in the 
presence of calcium ions. 
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1.3.2 With Metal Ions 
The interaction of polyuronates such as alginate with calcium 
ions has been discussed previously and has been described by Grant 
(1973) using the 'egg-box' model in which the interstices of the 
G-blocks of the alginate chains are filled with Ca2+ ions. For 
biological and biotechnological reasons, this system has received the 
greatest attention, but other divalent ions, for example Zn2+. Cu2+ 
and Cd2+, and some trivalent ions such as Bi3+ and Cr3+ have also 
been investigated (Cesaro et al 1988). 
Other divalent cations may be incorporated within junctions 
in a similar manner to calcium ions, but there are noticeable 
differences in the strength of binding, which have been widely 
investigated (Haug and Smidsr0d 1970, Kohn 1987). The selectivity 
of alginates for some divalent metal ions may be expressed 
quantitatively in terms of a 'selectivity coeffiCient' (Smidsr0d and 
Haug 1968), that is, the affinity of a polyanion to a metal ion relative 
to the affinity to another metal ion. 
The interaction of alginates with univalent cations (for 
example Na+, K+ and Li+) has been studied less extensively. 
However, after a series of experiments (Seale, Morris and Rees 
1982), it has been suggested that three types of interaction may 
occur between univalent cations and alginates in solution: 
(i) weak chelation by mannuronate and isolated guluronate 
residues; 
(ii) specific site-binding to adjacent guluronate reSidues: 
(iii) co-operative 'egg-box' binding, especially of Na+, 
between poly-L-guluronate sequences. 
The binding of iron by alginate has potential significance in 
the food and pharmaceutical industries. Since alginate is not 
generally absorbed in the small intestine where most iron is 
absorbed into the body, there is a possibility that sufficient ingestion 
of alginate could lead to decreased bioavailability of iron. Attempts 
have been made to relate iron bioavailability to the presence of 
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dietary polysaccharides. For example, Hannuth-Hoene and Schlenz 
(1980) demonstrated a decrease in iron absorption in rats when 
sodium alginate, carrageenan or agar constituted 10% of the diet. 
Wolbling et al (1980) showed that an artificial diet containing 100/0 
sodium alginate inhibited the absorption of iron in normal but not in 
iron-deficient rats. The in vitro binding of iron by sodium alginate 
has also been demonstrated (Berner and Hood 1983), although its 
effect on more complicated food systems is still unclear. 
Toxic heavy metals such as lead, cadmium and strontium are 
health hazards in industrial areas where they are contained in 
airborne dust particles. On inhalation, they may be deposited in the 
respiratory tract and passed into the gastrOintestinal tract. In vitro, 
there is evidence that alginates bind heavy metals, thus their 
possible uses in reducing absorption of these toxic chemicals in 
humans has been proposed. However, although in vitro and in vivo 
studies of binding of alginate to heavy metals are widespread, they 
are often contradictory. 
For example, in vitro studies in isolated rat jejunum and 
duodenum demonstrated that the uptake and absorption of 
strontium is inhibited byalginates (Moore and Elder 1965, Patrick 
1967). These results are confirmed by in vivo investigations (Carr 
and Nolan 1968). However, for lead, alginates have been shown to 
decrease absorption in newborn rats fed a milk diet, but to increase 
absorption over a three day period in adult rats fed a standard diet 
(Carr et al 1969). 
According to Rose and Quarterman (1987), aqueous solutions 
of alginic acid bound lead and cadmium in vitro. In vivo, however, 
addition of alginic acid to the diet of rats was shown to increase lead 
retention, but had no effect on cadmium. In humans, no effect of 
alginates on the absorption of lead could be demonstrated (Harrison 
et al 1969). 
As can be seen, the reported findings are inconclusive and, as 
yet, there is little information which suggests definite benefiCial 
effects of dietary fibres such as alginates in reducing accumulation of 
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heavy metal in humans. However, as already mentioned, sodium 
alginate may be administered in a nuclear accident in order to bind 
radioactive strontium ions (section l.2.2). 
1.3.3 With Other Polysaccharides 
Interactions between algmates and pectin were originally 
observed in the food industry. When a 20/0 solution of sodium 
alginate from Laminaria hyperborea was added to a fruit product 
such as apple puree, with a sugar content below 300k, it was found 
to form a heat-reversible gel. which led to the conclusion that an 
interaction had taken place between the pectin in the fruit and the 
added alginate (Toft 1982). Toft noted that the above gels 
demonstrated freeze-thaw stability and that the nature of the gel was 
influenced by pH, sugar concentration and hydrocollOid 
concentration. 
Other workers reported that mixtures of alginates and 
pectins formed firm resilient gels at low pH, in the absence of 
calcium ions or high sugar concentrations (Steinnes 1975). 
I t has since been demonstrated that combinations of alginate 
and pectin produce gels under conditions at which neither 
polysaccharide forms gels independently (Oakenfull et al 1990). 
Stronger gels are produced from mixtures of pectins with high 
methoxyl content and alginates with high guluronate content in a 
ratio of pectin : alginate of approximately 1: 1 (Thorn et al 1982). 
Thorn and co-workers have proposed a theory for this 
interaction between alginates and pectins. The optimum interaction 
is found between homopolymeric sequences of L-guluronic acid 
reSidues in the alginate (Figure l.8). and methyl esterified 
D-galacturonic acid residues in the pectin (Figure l.9), at low pH in 
the absence of calCium ions. Molecular modelling has shown that 
these ribbons can pack together in parallel. two-fold, crystalline 
arrays with no cavities between the polymer chains. Each methyl 
group on the galacturonic acid chain can be opposed to the 
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Figure 1.8 L-guluronic acid residues (alginate) 
000-
o 
o 
Figure 1.9 D-galacturonic acid residues (pectin) 
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hydrogen atoms attached to C(l) and C(2) of the guluronic acid 
residues. thereby minimising their interaction with water. Since the 
effiCient packing of the chains requires minimal binding of water 
molecules for stability. the mixed structure is strongly favoured. 
Both polyguluronate sequences and polygalacturonate 
sequences chelate calcium ions strongly to fonn 'egg-box' structures. 
Therefore. if calcium is present when the pectin/alginate mixture is 
being aCidified. the ordered binding of alginate chains with other 
alginate chains. and pectin chains with other pectin chains. 
counteracts the fonnation of mixed junction zones. This explains 
why the addition of Ca2+ during the aCidification process confers 
poor gelation properties. However. it has also been found that if 
pectin/ alginate mixtures are first aCidified to fonn a gel and then 
Ca2+ ions are dialysed in. even stronger gels are fonned. probably by 
the formation of additional calcium -mediated junction zones which 
reinforce the original gel structure. 
1.3.4 With Proteins 
Interactions between proteins and polysaccharides occur 
frequently in biological systems. for example in such materials as the 
connective tissues of animals and in the membranes in certain eggs 
(Ledward 1979). Much of the reported work on protein-
polysaccharide interactions has been carried out using ionic 
polysaccharides. as it has been demonstrated (Ganz 1974) that there 
is little or no interaction between proteins and non-ionic 
polysaccharides. 
Imeson et al (1977) indicate that the major forces 
responsible for the interactions of myoglobin and bovine serum 
albumin with alginates. pectate and carboxymethylceUulose are 
electrostatic. involving the carboxylate groups of the polysaccharides 
and the positively-charged protein residues. for example amino and 
imidazole groups. Other workers. including Bernal et al (1987) and 
G o n ~ a l v e s s and co-workers (1986) have also demonstrated the 
-27-
electrostatic nature of protein-polysaccharide interactions. 
Stainsby (1980) suggested that it is possible that non-ionic 
interactions such as covalent bonds. hydrogen bonds or hydrophobic 
bonds may also have an important role in complex formation 
between proteins and polysaccharides. This is supported in a British 
Patent by Agfa (1964). who describes an interaction between 
propylene glycol alginate and gelatin under slightly alkaline 
conditions. which results in the formation of a gel with a melting 
point greater than 100oC. The predominant interactions in this gel 
would appear to have the thermal stability associated with covalent 
rather than ionic bonding. 
Mohamed and Stainsby (1984) studied interaction and gel 
formation between propylene glycol alginate and various proteins 
including gelatin. They noted that the optimum conditions for gel 
formation were pHs in the range 9.3-9.6. Gels produced using 
untreated gelatin were found to be resistant to prolonged heat 
treatment. However. when the amino groups of the gelatin were 
converted to hydroxyl groups using nitrous acid. it was found that 
gels of much lower melting pOints were produced. Therefore. the 
interaction is proposed as being a covalent linkage between the 
polysaccharide and the protein. involving the amino groups on the 
gelatin. McKay et al (1985) further expand this theory. It was known 
that highly esterified alginates were required for the interaction 
(McDowell 1970). thus it is suggested that the most probable 
reaction is amide formation between the esterified carboxyl groups 
on the polysaccharides and the uncharged amino groups on the 
gelatin. The optimum pH range of 9.3-9.6 found by Mohamed and 
Stainsby (1984) supports this theory. since the number of 
uncharged amino groups present for interaction increases from 
about pH 9. However. beyond pH 9.6 the increase in uncharged 
amino groups and the resultant increase in reaction rate gives rise 
to the fonnation of grossly inhomogeneous gels because suffiCient 
mixing of reagents is virtually impossible. 
The addition of calCium ions to the polysaccharide/protein 
systems complicates the interactions. since the components may 
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then interact in more than one way. Both the polysacchande and the 
protein could interact with Ca2+ ions. Alternatively. they could 
interact with themselves or with each other. with or without the 
involvement of Ca2+ ions (Hughes et al 1980). Guiseley (1980) 
suggests that. in solution. the anionic groups of ionic 
polysaccharides may interact not only with cationic molecules. but 
also with other anions via cation 'bridges' when divalent metal ions 
such as calcium are present. 
In dilute solutions, complexing between proteins and 
polysaccharides usually occurs at pH values below the protein 
isoelecmc point, that is, when the polyelectrolytes have opposite 
charges. so that complexation is mainly electrostatic in nature. 
However. addition of polyvalent metal ions such as Ca2+ may result 
in complex formation at pH values above the protein isoelectric 
point (Gluskey et al 1969. Hill and Zadow 1978). It is thought that 
the Ca2+ ions act as bridges. resulting in the fonnation of a triple 
complex of the form 
PROTEIN - DIVALENT METAL ION - POLYSACCHARIDE. 
Bernal et al (1987) added Ca2+ ions to the protein/ 
polysaccharide systems described above, but did not suggest a 
specific molecular model for the interactions occurring in the 
mixed polysaccharide-protein-calcium ion gel systems. 
Sherys et al (1989) investigated the formation of water 
insoluble triple complexes between bovine serum albumin and 
sodium alginate in the presence of bivalent metal cations. especially 
copper. They propose that the insoluble triple complexes 
BOVINE SERUM ALBUMIN - CU(II) - ALGINATE 
form due to bridging between the copper-binding sites of bovine 
serum albumin and alginate carboxyl groups via Cu2+ cations. 
However. the exact structure and mechanism of fonnation of triple 
c0I11plexes of this kind is not yet known. 
-29-
1.4 PHARMACEUTICAL INTERACTIONS 
1.4.1 Dru&s and Excipients 
In the food industry the numerous interactions of 
macromolecules in solution are viewed as an advantage. giving 
alginates and other hydrocolloids a variety of useful applications 
according to their individual properties (section 1.2). However. in 
the pharmaceutical industry, the interactions are seen traditionally 
as a disadvantage, since an active constituent of a preparation may 
interact with a macromolecular component in a manner that, for 
example, impairs drug release after administration, or inhibits 
preservative efficiency. 
For example, it has been demonstrated that alginate binds to 
surfactants (Hayakawa et al 1983) which are often important 
stabilising components of pharmaceutical fonnulations. Interactions 
with alginate may reduce the efficacy of quarternary ammonium 
preservatives. and it is reported that cationic antiseptics. including 
acriflavine chlOride and cetylpyridinium chloride become inactivated 
in 10/0 ammonium alginate gel as a result of complex fonnation 
(Keipert et al 1973). 
Becirevic and Petricic (1980) studied the interaction of the 
antitussive noscapine chloride with various macromolecular agents 
including sodium alginate. using equilibrium dialysis. with a view to 
formulating oral liquid dosage fonns. Their results indicate that 
noscapine chloride interacts with anionic species such as alginate. 
The authors view this interaction as a disadvantage, and it is 
suggested that 'in fonnulating a preparation that requires a 
combination of such materials. interacting macromolecular adjuvants 
should best be avoided'. 
Habib et al (1991) reported an interaction between 
chloramphenicol and certain water-soluble macromolecules. such as 
polyethylene glycols, which affected the bioavailability of the drug 
and could therefore reduce its efficacy as an antimicrobial against 
Streptococcus bacteria. 
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Another drawback is that interactions may increase the 
resistance of certain bacteria to antibiotics. The exopolysaccharide 
of certain bacteria, for example, Pseudomonas aeruginosa. is a 
polyuronide similar in structure to alginates (Linker and Jones 
1964). Pseudomonas aeruginosa is commonly found in patients with 
cystic fibrosis, a fatal inherited disease, and with other chronic lung 
diseases (Gill et al 1987). 
In 1981, Slack and Nichols published findings that the 
diffusion of aminoglycoside antibiotics, for example, gentamicin and 
neomycin in vitro is retarded by sodium alginate and by the 
exopolysaccharide of a mucoid strain of Pseudomonas aeruginosa. 
Tannenbaum and co-workers (1984), in apparent conflict 
with these findings, reported the inability of Pseudomonas 
aeruginosa to bind the antibiotics streptomycin, tobramycin, 
clindamycin and penicillin at physiological concentrations of saline. 
and therefore considered that the exopolysaccharide of 
Pseudomonas aeruginosa did not provide increased antibiotic 
resistance. 
However, Nichols et al (1988) have now demonstrated that 
binding of the aminoglycoside antibiotic tobramycin does occur In 
the presence of alginate and exopolysaccharide from Pseudomonas 
aeruginosa. but that the level of binding which occurs in 
physiological buffer solutions is lower than that which could have 
been detected by the method of Tannenbaum et al (1984). 
In vitro, this binding inhibits diffusion of the antibiotic to its 
target sites, probably by reducing the free concentration of the drug 
available for diffusion. These results have been supported by the 
findings of Gordon et al (1988), who reported that gentamicin and 
tobramycin 'bound avidly' to both commercial and Pseudomonas 
alginates. 
1,4,2 Possibilities for Controlled Dn'f Release 
Despite the apparent disadvantages of drugs Interacting with 
macromolecular ingredients of a formulation. studies have been 
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undertaken which investigate the potential of using these 
interactions in order to control the delivery of various drugs. 
For example. in 1961 and 1962. Graham and Thomas began 
studying the interactions of alginate. carrageenan and other 
hydrocolloids with alkaloids such as quinine. hyoscyamine. caffeine 
and theophylline. In a paper published in 1963. Graham et al 
conSidered that if highly insoluble complexes could be obtained 
from the interaction of various tranqUilizers and hypotensive agents 
with hydrocolloids such as alginate. there was a possibility that 
controlled release forms of the drugs could be developed. Their 
interaction studies indicated that sodium alginate forms preCipitates 
with the drugs promazine. chlorpromazine and reserpine. thus 
making the complexes 'potentially suitable as sustained release 
forms of these and possibly other drugs'. 
More recently. Beldie et al (1989) have employed the 
interaction between neomycin and xanthan gum to form a delayed 
release complex. which was found to exhibit zero-order release 
kinetics when using artifiCial tear solution as the eluent. The authors 
suggest that it could be used to form ocular inserts for controlled 
release of drug. 
Kawashima and co-workers (1989) prepared sustained 
release suppositories containing the antibiotic bacampicillin. In 
aqueous solution. the interaction of bacampicillin with alginic acid 
produced a slightly water-soluble complex. which was presumed to 
be linked by ionic bonding and was reportedly chemically stable. 
Simple physical mixing of sodium alginate with bacampicillin in a 
suppository base prolonged absorption of the drug in rabbits without 
a marked decrease in bioavailability compared to that after 
administration of bacampicillin alone. Furthermore. the absorption 
rate could be controlled by the amount of alginate added. The 
authors suggest that. after the suppository containing both 
substances dissolves. there may be Simultaneous fast absorption of 
'free' bacampicillin. together with formation of a 
bacamplcillin/ alginate ionic complex from which the drug Is 
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released slowly over a prolonged period. Similar sustained- release 
suppositories containing morphine mixed with alginate were 
prepared (Kawashima et al 1990), which the authors suggest could 
be clinically useful. since prolonged absorptions were obtained by 
the addition of up to 50% alginate, without a decrease in 
bioavailability compared to that found in rabbits after oral 
administration. 
Tucker et al (1988) studied the complexation of propranolol 
hydrochloride with carboxymethylcellulose. They suggest that with 
increasing concentration of propranolol. an increasing proportion of 
the carboxyl groups of the carboxymethylcellulose become occupied. 
until an insoluble complex is formed. Their binding data also 
indicated that there was more than one binding site. or that 
co-operative binding was occurring. That is. propranolol binds to the 
carboxyl groups on the carboxymethylcellulose until some fraction is 
occupied and precipitation occurs. Binding then continues to 
carboxyl groups on the preCipitate. Tucker et al go on to suggest 
that such interactions may influence the bioavailability of a given 
product. 
However, Hussain et al (1980b) incorporated methylcellulose 
into a nasal formulation of propranolol as a method of controlling 
release of the drug. They reported lower maximum blood levels of 
the drug (than when not incorporating methylcellulose). but that 
these were sustained over a longer period of time, such that there 
was an almost identical bioavailability. 
This review has outlined the potential uses of macromolecular 
interactions in controlling drug delivery. The possibilities for other 
delivery systems employing macromolecules to achieve controlled 
release of drugs are conSiderable, and it is a field which obviously 
requires further investigation. 
In the following work, we have studied the interaction of the 
anioniC polysaccharide sodium alginate with propranolol 
hydrochloride, a model cationic drug, with a view to obtaining 
controlled release of drug both in vitro and in vivo. 
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1.5. AIMS AND OBJECTIVES 
The overall aim of the work presented in this thesis was to 
achieve a greater understanding of the fundamental mechanisms 
controlling the interaction of an anionic polysaccharide polymer 
with an oppositely-charged drug molecule in an aqueous 
environment, and to investigate the potential of the ionic 
polysaccharide/drug complex fonned as a controlled release drug 
delivery system. 
Sodium alginate (from either Laminaria hyperborea or 
AscophyUum nodoswn species) was chosen as a model anionic 
polysaccharide and the following objectives were established in 
order to investigate its usefulness as part of a drug delivery system 
for controlled release: 
1. To characterise of the alginates in tenns of molecular 
weight, polydispersity and M:G ratio. 
2. To investigate the interaction of the alginates with the model 
cationiC drug propranolol hydrochloride and to study the 
effect of counter-ions such as sodium chloride on this 
interaction. 
3. To quantify the interaction between the alginates and 
propranolol hydrochloride and to model the possible 
structure of any complex fonned. 
4. To prepare a convenient dosage form from the propranolol/ 
alginate complex and to investigate the drug release 
properties of this formulation in vitro and in an in vivo animal 
model. 
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CHAPTER 2 CHARACTERISATION 
2.1 INTRODUCTION - WHY CHARACTERISE? 
A knowledge of molecular weights. molecular weight 
distributions. M:G ratio and polydispersity has been found to be of 
fundamental importance for many pharmaceutical and non-
pharmaceutical applications of alginates. For example. in the food 
industry. the presence of low molecular weight 'tails' of alginate is 
detrimental to their use as gelling and thickening agents (Launay et 
al 1986). In the oil industry. polysaccharides are often added to 
fluids injected for mobility control in flooding operations. and the 
effectiveness of the polysaccharide in this context has been shown 
to be largely dependent on its molecular weight (Holzwarth 1985). 
In the pharmaceutical field. polysaccharides are increasingly 
being used as potential drug delivery systems. for example. as 
carrier systems for drug targeting (Friend and Pangburn 1987). for 
sustained release (Melia 1991). and as bioadhesives for increasing 
the transit times of novel dosage forms in the small intestine 
(Anderson et al 1989). The performance and usefulness of these 
delivery systems depend greatly on the properties of the carrier 
system. which in turn depends in part upon the molecular 
characteristics of the polysaccharide used. In addition. any excipient 
which is to be used medically is required to be well characterised in 
order to avoid toxic reactions within the human body. Therefore. 
quite apart from the necessities of scientific investigation. when 
employing a polysaccharide in a drug delivery system. it is important 
that it is thoroughly characterised. 
A systematic approach to the investigation of variables such 
as molecular weight, M:G ratio, polydispersity and polyelectrolyte 
behaviour for the manipulation and control of alginate interaction 
with specified drugs represents an excellent method for developing 
novel drug delivery systems. 
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The molecular weight and polydispersity of alginates are 
fundamental to their characterisation since they affect many other 
physical properties. for example. viscosity. osmotic pressure and 
gelation. These properties may influence the way in which an 
alginate delivery system releases drugs. 
The M:G ratio of an alginate may also be important when 
studying possible complexes for drug delivery. It has already been 
demonstrated that G-blocks bind Ca2+ ions more strongly than 
M-blocks or MG-blocks (Grant et al 1973). Therefore. it is intended 
to study drug interactions with alginates possessing different M:G 
ratios. in order to investigate the possible usefulness of the M:G ratio 
as a tool for controlling drug delivery. 
Finally. alginates are ionic, therefore the possibilities for 
electrostatic interactions with oppositely-charged drugs are 
countless. Electrostatic interactions may be easily altered by. for 
example. changes in solution pH or ionic strength. These are 
potentially useful drug release triggering mechanisms in vivo. 
Two highly purified sodium alginates from Protan 
LaboratOries. Norway were employed in this research project. which 
had been extracted from the brown seaweeds Laminaria hyperborea 
(batch number 902-282-904) and from AscophyUum nodosum 
(batch number 911-211-04). The techniques used for 
characterisation of these alginates included: 
(1) gel permeation chromatography (with and without multi-angle 
laser light scattering): 
(il) 'low speed' sedimentation eqUilibrium in the analytical 
ultracentrifuge: 
(iii) nuclear magnetic resonance spectroscopy. 
In addition, the following information regarding the purity of 
the alginates was supplied by the manufacturer: 
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Product name: 
Batch number 
Particles: 
Protein content: 
Metal ion content: 
Ca 
Mg 
01 
Zn 
Si 
Sr 
Fe 
Mn 
Pb 
As 
Hg 
Laminaria hyperborea 
a l ~ i n a t e e
902-282-04 
Filtered through 
0.2 micron fIlter 
0.240/0 
23ppm 
7ppm 
2ppm 
20ppm 
<lppm 
2ppm 
33ppm 
3ppm 
10ppm 
70ppb 
<10ppb 
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AscoQhyUum nodosum 
a l ~ i n a t e e
911-211-04 
Filtered through 
0.2 micron fIlter 
0.12% 
422ppm 
6ppm 
13ppm 
8ppm 
<0.5ppm 
45ppm 
55ppm 
<2ppm 
<10ppm 
82ppb 
<30ppb 
2.2 GEL PERMEATION CHROMATOGRAPHY I MULTI-ANGLE 
LASER LIGHT-SCATTERING (GPC/MALLSl 
2.2.1 Introduction 
Gel permeation chromatography (GPC) or gel filtration was 
first introduced in 1959 as a method for 'desalting and group 
separation' (Porath and Flodin 1959). Since then it has been used 
extensively in the purification and separation of many biological 
macromolecules, for example, enzymes, polysaccharides, nucleic 
acids and proteins. 
In a typical GPC experiment, a column of known length and 
diameter is packed with a porous gel (the stationary phase) through 
which sample molecules pass suspended in an eluent, such as a 
buffer solution (the mobile phase). Movement through the gel bed 
depends on the flow rate of the mobile phase and the Brownian 
motion of the solute molecules which causes them to diffuse in and 
out of the stationary phase. 
The separation of molecules in GPC depends on the different 
abilities of the sample molecules to enter pores in the gel. Very 
large molecules cannot enter the pores and thus move through the 
gel bed fastest. Smaller molecules which can enter the pores move 
more slowly throughout the column. Molecules are therefore eluted 
in order of decreasing molecular size. 
Results from GPC experiments are usually presented as an 
elution profile, showing the variation of solute concentration in the 
eluent against the volume of eluent passed through the column. 
Other parameters obtained include VO, the void volume and Vt, the 
total volume. Vo is the aqueous phase surrounding the gel beads and 
can be determined easily as it is the volume required for elution of a 
molecule so large as to be completely excluded from the gel pores. 
V t is the total volume of the packed gel bed and therefore 
corresponds to the volume of eluent required to elute a molecule 
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small enough to be completely included on the column. Thus Vo and 
V t represent the exclusion limits of the column, since all molecules 
will be eluted between Vo and Vt unless some other phenomenon. 
for example, adsorption is occurring. 
Vo and V t can be determined experimentally using 
appropriate molecules. For the purpose of these experiments, blue 
dextran 2000 was used to determine VO, as it is both large and 
coloured, and is therefore also useful for checking correct packing 
of the gel bed since the colour allows a visual check that the sample 
is flowing in a straight band. Marshall (1970) pOints out that blue 
dextran 2000 should always be used fresh, as old solutions have been 
shown to bind to column materials. Vt was determined using 
sucrose, although other small molecules such as potassium chloride 
are suitable and are often employed. 
2.2.2 Applications of Gel Penneation C h r o m a t o ~ h y . .
The more important applications of GPC include: 
determination of molecular weights and molecular weight 
distributions; group separation and fractionation; separation of cells 
and particles. 
GPC is an excellent technique for determining molecular 
weights and molecular weight distributions, provided that adequate 
average standards exist which enable the column to be calibrated for 
a given molecule, or that suitable absolute molecular weight 
detectors can be incorporated downstream of the column .. It has 
been paticularly successful with proteins as it allows the molecular 
weight to be measured under a wide range of conditions of pH, ionic 
strength and temperature. 
When determining molecular weight distributions, the elution 
profile may be recorded continuously or by collecting fractions and 
analysing them. Once a calibration curve has been determined for a 
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given macromolecule on a given column, it may be applied to a large 
number of runs, because the chromatographic behaviour of the 
column is extremely reproducible. However, the main problem is 
fmding standards with which to calibrate the column. Typically, for 
polysaccharides, dextrans or similar compounds are used, but they 
are less suitable as standards for polysaccharides which differ greatly 
from dextrans in terms of their shape and conformation in solution. 
Group separation involves separating molecules which differ 
greatly in size. Thus, applications include desalting of proteins and 
other large molecules prior to concentration, removal of free low 
molecular weight labels, for example, 1251, from labelled molecules, 
and termination of reactions between macromolecules and low 
molecular weight reactants. Fractionation involves separating 
molecules of similar sizes and is therefore a useful technique for the 
purification of many biological macromolecules. 
GPC has wide applications for separating cells and particles. 
For example, it has been used to separate erythrocytes from human 
blood (Kankura et al 1974), to remove monocytes from peripheral 
blood leucocytes (Alonso et al 1978), and also as a method for the 
preparation of platelets from blood plasma (Tangen et al 1971). 
2.2.3 GPC/MALLS 
Polysaccharide molecular weights are frequently determined 
by light scattering techniques. In traditional laser light scattering 
experiments, the sample is isolated in a cell, and there is one 
photomultiplier tube which is moved to different angles in order to 
measure the angular dependence of the scattered light. 
A recent innovation has been to replace the isolated sample 
cell, containing a discrete quantity of solution, with a cell in the 
form of a glass block of narrow bore through which the solution 
flows at a constant rate. The angular dependence of the intenSity of 
scattered light is measured by apprOximately 15 detectors situated 
around the cell. Thus, if the polysaccharide solution is first passed 
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through a GPC column (where it will have been fractionated 
according to molecular size) and from there passes into the sample 
tube described above. the molecular weight distribution of the 
polysaccharide can be determined. This technique is referred to as 
gel penneation chromatography/multi-angle laser light-scattering or 
GPC/MALLS. 
2.2.4 Materials 
Laminaria hyperborea alginate. BN 902-282-04 (Protan 
Laboratories. Norway); 
Disodium hydrogen phosphate BN 71647162 (Fisons. 
Loughborough) ; 
Potassium dihydrogen phosphate BN 33757060 (Fisons. 
Loughborough) ; 
Sodium chloride BN 6794910K (BDH. Poole. Dorset); 
Sephacryl S-400 (Pharmacia. Milton Keynes): 
Phenol BN 108 (Fisons. Loughborough): 
SulphUriC acid 950/0 (Fisons. Loughborough); 
AnaLar deionised water BN 3137510L (BDH. Poole. Dorset). 
All were used as received. 
2.2.5 Methods 
2.2.5.1 GPC 
The principal alginate used for the work in this thesis. a 
highly purified sodium alginate produced from the Laminaria 
hyperborea species was used. The solvent used was a standard 
phosphate buffer of pH 6.5. containing Na2HP04 and KH2P04 made 
up to an ionic strength of 0.3 using NaCI in accordance with Green 
(1933). The gel used was Sephacryl S-400 superfine. 
The sodium alginate was made up to a volume of 5mL and 
applied to a column of Sephacryl S-400 superfine (1.6cm internal 
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diameter x 85cm). The loading concentrations were approximately 
0.4 mg mL-I, and these were run in the phosphate-chloride buffer 
described above at a flow rate of approximately 10 mL h -1. 2ml 
fractions were assayed for total sugar content using the phenol-
sulphuric acid assay for total sugar content described by Dubois et al 
(1956). In summary, ImL of 5%w jv phenol was added to sample 
volumes of ImL and the mixture vortexed. 5mL of concentrated 
sulphuric acid was added vigorously to the liquid surface and it was 
vortexed again. The solvent was used as blank and after 30 minutes, 
absorbance at 485nm was recorded against the blank. 
The void volume V 0 was determined using blue dextran 2000 
and the total volume Vt using sucrose. Recoveries from the column 
were between 90 and 1000/0. 
Each column run was performed in triplicate under the same 
conditions in order to check the reproducibility of the results. 
Standard deviations were found to be < 0.03 in all cases. 
2.2.5.2 GPC/MALLS 
A schematic diagram of the GPCjMALLS system used is 
shown in Figure 2.1. A Wyatt Technology Dawn F mUlti-angle laser 
light-scattering photometer was used to examine the molecular 
weight distribution of the purified alginate from Laminaria 
hyperborea mentioned above. Solutions of the sample (0.5-5.0mg 
mL -I) were made up in the phosphate-chloride buffer described 
above, with an ionic strength of O.IM or 0.3M. Buffer was then used 
as a mobile phase to wash the sample from the rheodyne, through 
the GPC column and into the light scattering cell. For data analysis it 
was necessary to know the concentration of the solution passing 
through the scattering cell at any given instant. This was achieved by 
measuring the refractive index of the solution using a differential 
refractometer placed after the light-scattering cell as shown in 
Figure 2.1. A computer was used to process and analyse the data 
from the GPCjMALLS system, in order to produce molecular weight 
distributions. 
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2.2.6 Results and Discussion 
Figure 2.2 shows the elution profile of the highly purified 
Laminaria hyperborea alginate. The plot is normalised by plotting 
Absorbance/Maximum Absorbance versus Elution Volume in order to 
correct for small differences in the loading concentrations of the 
alginates. Values obtained for Vo and Vt for the column used in 
these experiments were 60mL and 164mL respectively. 
Phenol in the presence of sulphuric acid can be used for the 
quantitative determination of sugars, their methyl derivatives, 
oligosaccharides and polysaccharides. The phenol-sulphuric acid 
assay (DubOis et al 1956) was chosen for these experiments because 
it is simple, rapid, sensitive and gives reproducible results. It should 
be pointed out, however, that the sensitivity of the assay is such that 
even slight contamination of glassware can give rise to very high 
estimations of polysaccharide content. Therefore. as with all 
analytical work, a rigorous system of cleaning and drying equipment 
was essential. Despite this problem. the authors claim that 'under 
the proper conditions the method can be expected to be accurate to 
within + 2%'. 
The elution profile is a function of an individual 
polysaccharide and therefore differs for different polysaccharides 
and indeed for different types of alginate. Valuable information 
concerning the polydispersity of compounds is gained from GPC: 
Figure 2.2 illustrates the polydisperse nature of the alginate. that is, 
the presence of non -interacting components of different molecular 
weight or composition. 
For many GPC runs it is possible, using standards of known 
molecular weight, to convert the elution profile into a molecular 
weight distribution. Unfortunately, for alginates and many other 
polysaccharides, there are no adequate standards since they differ 
immensely in shape and conformation in solution compared to, for 
example. globular proteins. 
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1.2 
Figure 2.2 Elution Profile of 
L. hyperborea Alginate 
Elution volume (mLl 
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Several possibilities have been suggested for overcoming this 
difficulty. For example, Ball et al (1988) proposed a technique for 
obtaining a molecular weight distribution for alginates using a 
combination of GPC followed by sedimentation equilibrium in the 
ultracentrifuge. However, this technique is time-consuming as it 
requires repeated GPC runs in order to obtain a suffiCient 
concentration of sample for the subsequent sedimentation 
eqUilibrium experiments. A more rapid technique is that of GPC 
combined with multi-angle laser light-scattering (MALLS) as used in 
these experiments. In this case, the sample passes directly from an 
HPLC/GPC column into the light-scattering apparatus so that a 
molecular weight distribution may be obtained directly within hours 
as opposed to days. 
Figure 2.3 is an example of a plot of the cumulative molecular 
weight distribution of the L. hyperborea alginate used above. Figure 
2.4 shows the average molecular weights of the L. hyperborea 
alginate obtained by computer analysis of the GPC/MALLS data. It 
should be noted that the molecular weights obtained from this 
technique are virtually independent of loading concentration 
(compared to those obtained from sedimentation eqUilibrium in the 
following section 2.3). This is because the 'loading concentration' is 
a nominal value only, referring to the concentration of solution 
injected into the system. The solution becomes considerably diluted 
when it enters the rheodyne and meets the running phase of buffer. 
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Figure 2.3 1'ypical Cumulative Molecular Weight 
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2.3 SEDIMENTATION EQUILIBRIUM IN THE ANALYTICAL 
ULTRACENTRIFUGE 
2.3.1 Introduction 
In order to characterise the alginates in terms of molecular 
weight, WW SPEED SEDIMENTATION EQUILIBRIUM (LSSE) in the 
analytical ultracentrifuge was employed. This is an absolute 
technique, requiring no assumptions about shape or conformation in 
solution, and no calibration by standards of known molecular weight 
(Creeth and Harding 1982). 
Inside the ultracentrifuge, a solution of the sample, together 
with a blank sample of solvent, is held in a two-sector cell inside a 
rotor. When the centrifuge is switched on, the sample molecules 
begin to sediment outwards from the centre of rotation. This 
tendency to sediment is balanced by diffusional forces counteracting 
the concentrating effect of the sedimentation process. In LSSE, the 
rotor is spun at relatively low speeds (2,000-15,000 r.p.m.) such 
that an eqUilibrium is set up between the sedimentational and 
diffUSional forces described above. The position of the sample 
molecules within the cell is dependent on their molecular weight: 
under the centrifugal force, molecules of high molecular weight will 
sediment more rapidly than molecules of lower molecular weight, 
and will thus tend to accumulate nearer the base of the cell. 
The distribution of the sample at equilibrium (after 
approximately 72 hours for the alginate samples used) is recorded 
using Rayleigh interference optics. From these distributions, 
information about the molecular weight of the sample can be 
obtained. The system works by shining a monochromatic beam of 
light Simultaneously through the two sectors of the cell containing 
the sample solution and the pure solvent respectively. This produces 
'interference fringes'. These fringes will be deviated from a straight 
line by any difference in the refractive index of the two solutions, for 
example that caused by the p r e s e n c ~ ~ of solute molecules. Thus, it is 
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possible to observe a concentration distribution of solute across the 
cell, which is a direct reflection of the molecular weights of the 
individual species in the solution. Computer analysis of the fringes 
produced enables a 'weight-average' molecular weight to be 
calculated, that is, the mean molecular weight when components 
are counted by the 'weight' of each. 
When using sedimentation equilibrium with alginates, the 
molecular weight observed has been found to be highly dependent 
on the concentration of the sample. To overcome this problem, the 
'apparent' molecular weight is measured for a range of sample 
concentrations and then extrapolated to zero concentration to 
obtain the actual molecular weight. The relationship between 
apparent molecular weight and actual molecular weight may be 
expressed as follows (Harding and Johnson 1985): 
where: 
l/Mapp - 11M + 2Bc (1) 
Mapp = apparent molecular weight (in this case, that 
measured using sedimentation equilibrium): 
M 
B 
c 
= 
= 
actual molecular weight: 
2nd virial coefficient: 
concentration. 
Therefore. a plot of I/Mapp vs. c would be expected to be 
linear. and extrapolating to zero should elicit the actual weight 
average molecular weight. 
This approach has been taken in these experiments. 
2.3.2 Materials 
Laminaria hyperborea alginate, BN 902-282-04 (Protan 
Laboratories, Norway): 
Ascophyllum nodosum alginate, BN 911-211-04 (Protan 
Laboratories, Norway): 
Disodiuln hydrogen phosphate BN 71647162 (Fisons. 
Loughborough) : 
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Potassium dihydrogen phosphate BN 33757060 (Fisons. 
Loughborough) ; 
Sodium chloride BN 6794910K (BDH. Poole. Dorset); 
AnaLar deionised water BN 3137510L (BDH. Poole. Dorset). 
Beckman Model E analytical ultracentrifuge. 
All were used as received. 
2.3.3 Methods 
The purified sodium alginates from Laminaria hyperborea and 
AscophyUum nodosum species were used. dissolved in a standard 
phosphate-chlOride buffer. pH 6.5. containing Na2HP04 and 
KH2P04 made up to an ionic strength of 0.3 using NaCI in 
accordance with Green (1933). 
A Beckman Model E analytical ultracentrifuge was used. 
employing Rayleigh interference optics and an RTIC temperature 
measurement system. Molecular weight determinations were 
performed in 12mm or 30mm optical pathlength cells for a range of 
concentrations (0.2-2.4mg mL-1) of sodium alginate. Prior to 
sedimentation equilibrium. each sample was made up in the solvent 
described above and dialysed against this solvent. 
Initial sample concentrations were determined by dialysing a 
known volume of the original alginate-in-buffer solution against 
distilled de-ionised water to remove buffer salts. then drying to 
constant weight in a Gallenkamp vacuum oven at 70oC. 
2.3.4 Results 
Figure 2.5 and 2.6 are plots of apparent molecular weight 
versus concentration and 1/ apparent molecular weight versus 
concentration respectively for the L. hyperborea alginate. 
Similarly. Figure 2.7 and 2.8 are plots of apparent molecular 
weight versus concentration and 1/ apparent molecular weight 
versus concentration respectively for the A. nodosum alginate. 
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Figure 2.7 
Apparent Molecular Weight vs. 
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The plots of I/Mapp vs. concentration deviate from linearity 
above concentrations of around 1.0mg mL-I. This is probably due to 
the fact that the effects of non -ideality for alginates are particularly 
severe (Harding et al 1992). Therefore, even at concentrations of 
around 1.5mg mL-l, the systems do not behave in an ideal way, and 
do not fit equation (1). which is applicable to various other 
polysaccharide systems. However, below concentrations of 1.Omg 
mL -1, the graphs are relatively linear and allow extrapolation of the 
plots to zero concentration in order to obtain weight -average 
molecular weights. 
For L. hyperborea.. the actual weight-average molecular weight 
obtained by extrapolation from the graph is 200,000-230.000 
Daltons. For the A. nodosum alginate, the molecular weight obtained 
is 140,000-160,000 Daltons. 
2.3.5 Discussion 
Sedimentation equilibrium in the analytical ultracentrifuge as 
a means of determining polysaccharide molecular weights is not 
without its problems. A variety of factors contribute to the 
experimental difficulties: 
2.3.5.1 Thennodynamic non-ideality 
In general, polysaccharides are large molecules which may 
interact with solvent molecules or with each other, and therefore 
they have large thermodynamic excluSion volumes. In the case of 
alginate, the molecules are negatively-charged and thus also show 
polyelectrolyte behaviour. 
One definition of an ideal solution is that it is a solution for 
which the law of ideal entropy of mixing holds. Entropy Is a measure 
of the 'randomness' of a system, and this law states that. if there is 
no interaction between the molecules. the entropy of a mixture is 
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always greater than that of the pure components. The derivation of 
the law involves the assumption that all the solute molecules are of 
the same order of size as the solvent molecules. so that solvent and 
solute might be interchanged at random in a hypothetical lattice. 
However. this will not be the case for polysaccharides. Each 
macromolecule is many times larger than a solvent molecule so that 
a macromolecular solution better resembles one in which the solute 
particles are required to move together in clumps. Moreover. some 
polysaccharides self-associate and this effect is generally worsened 
at high solute concentrations. This can lead to gross over-estimation 
of molecular weight values. 
For this reason. the distribution of solute molecules in a 
macromolecular solution can never be entirely random. The centre 
of each molecule is excluded from a volume determined by the 
volumes occupied by all the other molecules and these solutions are 
therefore termed 'non-ideal'. The problems of non-ideality may be 
minimised in the LSSE technique by employing low solute 
concentrations (0.2-0.4mg mL-l) and long pathlength cells 
(Beckman 30mm). 
Also. LSSE is highly dependent on the concentration of the 
original sample, which is itself difficult to determine accurately. For 
the purpose of these experiments, the original concentration was 
calculated by drying to constant weight in a vacuum oven but, at 
best. this gives a measurement of concentration of no better than 
95010 accuracy. Therefore, there is a degree of uncertainty as to the 
accuracy of the measurement, due to the problems of determining 
concentration effiCiently. For this reason, the molecular weight 
measured is stated as being within a range of values (for example, for 
the L. hyperborea alginate this is 200.000 to 230.000 Daltons) as 
opposed to just a single value. 
2.3.5.2 Polydispersity 
Alginate consists of species of different molecular weights as 
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has been shown in the previous section on GPC (2.2). For this 
reason, molecular weights can only be expressed as averages. 
These may be: 
(1) Weight average molecular weights (Mwl. where the 
species in solution contribute according to their relative weights (as 
in LSSE); 
(ii) Number average molecular weights (Mnl. where the 
species in solution contribute according to their relative 
populations; 
(iii) Z-average molecular weights (Mz}, where the species in 
solution contribute according to the squares of their relative 
weights. 
In the determinations carried out here using LSSE, the 
weight-average molecular weight was the principal parameter 
obtained, with the GPC and GPC/MALLS results giving a good 
indication of the polydispersity of the alginate. 
2.3.5.3 Confonnation. 
The conformation of polysaccharides in solution is difficult to 
define in comparison to that of, for example, globular proteins. This 
may greatly affect the accuracy of those techniques for measuring 
molecular weight which reqUire assumptions about shape and 
conformation in solution, for example, dynamic light scattering, gel 
permeation chromatography and viscometry. For this reason, LSSE 
and GPC/MALLS are both good choices for measuring the molecular 
weight of polysaccharides as no assumptions about shape or 
conformation in solution are necessary. 
However, despite the problems described above, the 
molecular weight of 200,000 to 230,000 Daltons obtained by LSSE 
and by GPC/MALLS for the alginate from L. hyperborea compares 
favourably with estimations of its molecular weight using other 
techniques. Data from Paoletti (1989) on this alginate indicates the 
following results: 
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Technique: 
Wide angle light-
scattering. 
Low angle light-
scattering. 
Calibrated GPC 
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Molecular wei2h t 
obtained: 
217,000 
214,000 
201,000. 
2.4 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY OF 
ALGINATES 
2.4.1 Introduction 
Nuclear magnetic resonance spectroscopy (NMR), as its name 
implies. is concerned with the magnetic properties of certain 
atomic nuclei. notably the hydrogen atom or proton. and carbon 
13C. Studying an organic molecule by NMR spectroscopy enables the 
recording of differences in the magnetic properties of the various 
nuclei present. which gives infonnation on their molecular 
environment and thus pennits the deduction of the positions of the 
nuclei within the molecule. The theory of NMR is well documented 
(Kemp 1975) and it has become an extremely useful tool in the 
structural characterisation of organic molecules such as 
polysaccharides. 
An important feature of alginate in tenns of the way it 
interacts with certain counter-ions. for example. Ca2+ ions. is the 
M:G ratio. Using NMR, Grasdalen et al (1979. 1981 and 1983) have 
developed a method for characterising alginates which provides 
information not only about M:G ratio. but also allows the calculation 
of the average length of the G-blocks. the sites most important in 
binding with counter-ions (section l.3.2). Each monomer unit. diad 
or triad within the alginate chain gives rise to a peak at a particular 
'frequency' in the NMR spectrum. and the various peaks have been 
interpreted by Grasdalen et al. There are four possible diad 
frequencies: FGG; FGM; FMG; FMM; and eight possible triad 
frequencies: FGGG; FGGM; FMGG; FMGM; FMMM: FMMG: FGMM; 
and FGMG. The peak areas can be used to calculate the monomeric 
composition (M:G ratio) of the alginate. 
In the above series of papers. Grasdalen and co-workers 
delnonstrated that alginates do not have a regular repeating unit. 
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Moreover, the sequential arrangement of the two monomers 
(mannuronic acid and guluronic acid) could not be determined by 
the monomer composition (monad frequencies) alone, but also 
required measurement of diad and triad frequencies. These values 
can be measured using NMR techniques, and from them the M:G 
ratio and the average length of the G-blocks can be calculated as 
outlined in section 2.4.1.2 and Appendix 2. 
2.4.1.2 Equations 
The relationship between the monad and diad frequencies is given 
by. 
FG=FGG+FGM 
FM = FMM + FMG 
and FGG + FMG + FGM + FMG = 1 
(It should be noted that for long chains where the 
contribution from the end groups can be neglected, 
FGM = FMG). 
For the triad frequencies (long chain alginates): 
FG = FGGG + FMGG + FGGM + FMGM 
FGG = FGGG + FGGM 
FMG = FGM = FMGM + FGGM 
FMM = FM - FMG,GM 
The average length of the G-blocks within the alginate molecule can 
be calculated from: 
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2.4.2 Materials 
Laminaria hyperborea alginate. BN 902-282-04 (Protan Laboratories, 
NOIWay); 
AscophyUum nodosum alginate. BN 911-211-04 (Protan 
Laboratories. NOIWay); 
HydrochloriC acid (BDH. Poole. Dorset); 
Sodium hydroxide BN III (Fisons, Loughborough); 
AnaLar water BN 3137510L (BDH. Poole. Dorset); 
Leybold -Heraeus 'Lyovac GT2' freeze-drier; 
Bruker WM-500 NMR spectrometer. 
2.4.3 Methods 
The following method for alginates gave a degree of 
polymerisation of approximately 30-50 which ensured that the 
viscosity of the sample was not too high. The pH was reduced in 
stages. which prevented precipitating out of the alginate, which 
occurred if the pH was reduced in one large step. 
An alginate (1 OOmg) from either Laminaria hyperborea or 
AscophyUum nodosum species was dissolved in approximately 25mL 
of deionised water. The pH was adjusted slowly to 5.4 with O.lM 
HC!. This was then heated in a water bath at 1000 C for 1 hour. After 
cooling to room temperature the pH was adjusted to 4.6 with O.lM 
HC!. The solution was reheated in a water bath at 1000 C for 1 hour. 
then cooled to room temperature and the pH adjusted to 6.8 with 
O.lM NaOH. 
The alginate solution was then freeze-dried using a 
Leybold-Heraeus 'Lyovac GT2' drier. (The sample was placed in a 
round-bottomed flask. swirled in 'dry-ice'-in-acetone until frozen. 
then transferred to the freeze-drier for approximately 12 hours until 
dry). It was then re-dissolved in D20 ('heavy water') at a 
concentration of 10mg in 4mL D20. (This prevents the peak for 
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water in the NMR spectra obscuring other sample peaks and 
therefore provides better resolution). The sample was fmally 
freeze-dried again as described above. 
The proton spectra were recorded at 92°C using a Bruker 
WM-500 spectrometer. 
2.4.4 Results and Discussion 
The NMR spectra of the Laminaria hyperborea alginate and 
the AscophyUwn nodoswn alginate are shown in figures 2.9 and 2.10 
respectively. 
The monomer composition, diad and G-centred triad 
frequencies were determined from the 1 H -spectra as deSCribed by 
Grasdalen et al (1983). The area under the peaks on the NMR 
spectra were determined using computer software at the University 
ofTrondheim, Norway. Calculation of the M:G ratio and the average 
length of the G blocks is outlined in Appendix 2. 
Tables 2.1 and 2.2 illustrate the composition and sequence 
parameters for the L. hyperborea alginate and the A. nodoswn 
alginate respectively. These results indicate that the alginate from L. 
hyperborea has an M:G ratio of 35:65 and an average length of 
G-blocks of 6.2 residues, while the alginate from A. nodoswn 
alginate has an M:G ratio of 61:39 and an average length of G-blocks 
of 2.5 residues. 
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Table 2.1 Composition and Sequence Parameters 
for L. hyperborea alginate 
BN 902-282-04 
FG 0.647 
FM 0.353 
FGG 0.543 
FMM 0.249 
FGM,MG 0.104 
FGGG 0.470 
FGGM 0.073 
FMGM 0.031 
NG (average length 6.2 
of G-blocks) 
M:G ratio 35 : 65 
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Table 2.2 Composition and Sequence Parameters 
for A. nodosum alginate 
BN 911-221-04 
FG 0.389 
FM 0.611 
FGG 0.234 
FMM 0.456 
FGM,MG 0.155 
FGGG 0.168 
FGGM 0.066 
FMGM 0.089 
NG (average length 2.5 
of G-blocks) 
M:G ratio 61 : 39 
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2.5 CONCLUSIONS 
2.5.1. Lam.inaria hyperborea ~ t e e
(Protan Laboratories. batch number 902-282-04) 
This alginate has been characterised as follows: 
(i) Weight-average molecular weight: 200,000-230,000 Daltons (from 
LSSE, light-scattering and calibrated GPC measurements); 
(ti) Molecular weight distribution: refer to Figures 2.2 and 2.3; 
(iii) M : G ratio = 35 : 65: 
(tv) Average length of G blocks: 6.2 residues. 
2.5.2 Ascophyllum nodosum a1itJrutte 
(Protan Laboratories. batch number 911-221-04) 
This alginate has been characterised as follows: 
(1) Weight-average molecular weight: 140,000-160,000 Daltons (from 
LSSE measurements); 
(ii) M: G ratio = 61 : 39; 
(iii) Average length of G-blocks: 2.5 residues. 
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CHAPTER 3 
VISCOMETRY AND NEPHELOMETRY 
3.1 VISCOMETRY 
3.1.1 Introduction 
The formation of molecular complexes by soluble polymers in 
solution is usually associated with a modification of rheological 
behaviour (Keipert et al 1973). The addition of multivalent cations, 
for example calCium ions, to solutions of alginates increases the 
viscosity of those solutions as a result of interchain crosslinking 
(Smidsr0d and Haug 1972b: Penman and Sanderson 1972). At the 
outset of these studies, it was thought that the addition of a 
positively-charged drug to an alginate solution could have a Similar 
effect, thereby producing a drug trapped within an alginate gel, 
which could form the basis of a drug delivery system. Therefore, the 
following experiments were designed to measure the viscosity of 
alginate solutions. and to investigate the effect of adding a model 
positively-charged drug. propranolol hydrochloride, to those 
solutions. 
Viscosity is the property of a fluid which mainly characterises 
its 'flow' behaviour. The concept of viscosity involves the idea of 
internal 'friction' between molecules of the fluid. such that, 
whenever any part of the fluid is caused to move, neighbouring parts 
tend to be carried along also. This creates a resistance to 'flow', 
which forms the basiS of the quantitative measurement of viscosity. 
The presence of macromolecules in a solution generally has the 
effect of increasing the resistance to flow of that solution compared 
with the pure solvent. which can be measured as an increase in the 
viscosity of the solution using a suitable viscometer. 
-69-
The most common viscometers used are capillary 
viscometers. since they are comparatively simple, inexpensive. and 
reqUire only a small amount of test liqUid. Since the viscosity of a 
liqUid usually decreases with an increase in temperature. often by an 
appreciable amount (Dinsdale 1962). temperature control is 
essential. and is again relatively easy with a capillary viscometer. 
The viscometer used for these experiments was a V-tube 
capillary viscometer as deSCribed in the British Pharmacopoeia 
1988. 
3.1.2 Materials and Equipment 
V-tube viscometer size B, type PSL BS/V no. 1353. made of clear 
borosilicate glass complying with specifications to 
International Standards ISO 3104-1976 and 3105-1976: 
Viscometer bath (Townson and Mercer Ltd., Croydon): 
Laminaria hyperborea alginate (highly purified). BN 902-282-04 
(Protan LaboratOries. Norway): 
Laminaria hyperborea alginate (non-purified). BN 902-282 (Protan 
LaboratOries. Norway); 
Propranolol hydrochloride BN 8905237 (CP Pharmaceuticals, 
Loughborough) ; 
Sodium chloride, BN 6794910K (BDH, Poole, Dorset); 
AnaLar deionised water BN 3137510L (BDH, Poole, Dorset). 
All reagents were used as received. 
3.1.3 Methods 
The size of the viscometer to be used was determined by 
measuring the run times of sodium alginate solutions at 
concentrations of 0.0IgL-1, 0.1gL-l and 1.0gL-I. in viscometer sizes 
A, B. C and D. A size B viscometer was chosen for these experiments 
as it yielded run times of greater than 60 seconds for the lowest 
concentration of alginate being measured, but less than 15 minutes 
for the highest concentration (B.P. 1988). 
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ViscoSity determinations were carried out as described in the 
British Pharmacopoeia 1988. A100. Method 1. The apparatus used is 
illustrated in Fig 3.1. To summarise. the viscometer was fllled with 
the liquid being examined through tube L to slightly above the mark 
G. The tube was placed vertically in a viscometer bath at 250C 
(+ 0.1 OC). and left to equilibrate at this temperature for 15 minutes. 
The volume of liquid was adjusted so that the bottom of the 
meniscus settled at the mark G. The liquid was then sucked to a 
point approximately 5mm above the mark E. On releasing the 
suction. the time taken for the bottom of the meniscus to fall from 
the top edge of mark E to the top edge of mark F was measured. 
The mean value of five readings was taken. 
The viscosity of solutions of macromolecules is conveniently 
expressed by the ratio of the viscosity of the solution, 11. to the 
viscosity of the pure solvent. 110. This ratio is referred to as the 
'relative viscosity'. so that: 11rel = 11 / 110. The mean run-time 
(n = 10) of AnaLar deionised water (in the size B U-tube viscometer 
used in these experiments) was determined as 68.2 seconds by the 
method described above. All further run times of the alginate/ 
propranolol mixtures were converted into relative viscosities by 
comparison with this run-time value for water. 
Initially. solutions of both a non-purified and a highly-purified 
Laminaria hyperborea alginate (0.01gL-1 to 1.0gL-1) were examined. 
(The 'non -purified' was a standard industrial grade alginate. and the 
'highly-purified' was the same alginate which had undergone a 
rigorous purification process to remove contaminants such as 
polyphenols (section 1.1.5)). The effect of adding propranolol 
hydrochloride (0.00025M - 0.1M) on the viscosity of 0.5gL-1 and 
1.0gL-1 alginate solutions was then investigated. As a control, 
sodium chloride was added to the alginate solutions in the same 
proportions as propranolol hydrochloride. 
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Figure 3.1 U-tube Viscometer 
(BP 1988) 
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3.1.4 Results 
Figure 3.2 shows the relative viscosities for solutions of 
Laminaria hyperborea alginates (purified and non -purified) in AnaLar 
deionised water. 
Figures 3.3 and 3.4 show the effect of adding propranolol 
hydrochloride to the alginate solutions, compared with the effect of 
adding sodium chloride solution (control), for the non-purified and 
purified alginate respectively. 
3.1.5 Discussion 
From Figure 3.2, it can be seen that increasing the 
concentration of alginate in the solution increased its viscosity as is 
expected, due to the presence of increasing numbers of the 
highly-extended alginate molecules restricting the 'flow' of the 
solution. 
For both types of alginate, the addition of propranolol or 
sodium chlOride caused a decrease in the viscosity of the alginate 
solutions. In general terms, this may be explained in terms of the 
shape of the alginate molecules in solution, since, to a large extent, 
this determines the flow properties, and therefore the viscosity, of 
the solution. The shape of the flexible charged alginate molecules 
will vary depending on the degree of ionisation. Therefore, in an 
aqueous solution, the alginate molecules will be expanded due to 
mutual charge repulsion between the alginate molecules and the 
water molecules, and the viscosity increases. On addition of small 
counter-ions such as sodium ions, the effective charge is shielded 
and the alginate molecules contract causing the viscosity to decrease 
(Smidsr0d 1979). 
However, the viscosity decrease on addition of propranolol 
was greater than that observed on addition of sodium ions (control) 
at the same concentration (Figures 3.3 and 3.4). It was observed 
that. above a certain concentration of propranolol (apprOximately 
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Figure 3.2 Viscosity of Non-Purified and 
Purified L. hyperhorea Alginate Solutions 
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Figure 3.3 
Viscometry of Alginate/Propranolol and 
Alginate/Sodium Chloride Mixtures: 
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Figure 3.4 
Viscometry of Alginate/Propranolol and 
Alginate/Sodium Chloride Mixtures: 
Purified L. hyperborea Alginate 
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O.007M when mixed with the 19L-1 alginate solutions), a 
white-coloured precipitate was fanned. This phenomenon was not 
observed in the alginate/sodium chloride mixtures, therefore it was 
concluded that an interaction was occurring between the alginate 
and propranolol hydrochloride which was causing a preCipitate to be 
formed. In this case, two effects contribute to the decrease in 
viscosity observed. There is charge shielding (as described above for 
addition of sodium ions above) but, in addition, there is a decrease 
in solubility, resulting in the fonnation of a preCipitate and a further 
decrease in viscosity as the polymer is removed from solution. Thus, 
the alginate / propranolol mixture behaves as a relatively non -viscous 
liquid (with a relative viscosity almost equal to that of the pure 
solvent) containing particles of preCipitate. 
It was decided to examine various mixtures of alginate with 
propranolol in order to study the fonnation of the preCipitate 
observed in the previous experiments, and to quantify the point of 
precipitation for different types of alginate. The technique chosen to 
perform this was nephelometry. 
3.2 NEPHELOMETRY 
3.2.1 Introduction 
Nephelometry, a simple but sensitive technique for 
measuring the turbidity of liqUids, has been utilised for many 
decades for measuring bacterial growth. In addition, it has found 
applications in the fields of brewing, water analysiS, food and 
manufacturing chemistry (E.E.L. 1976). and has the advantage that 
measurements can be made without disturbing the test liqUid. 
Nephelometry works on the principle of light-scattering. so 
that light shining onto the test liqUid becomes scattered if the liqUid 
is turbid or cloudy. Connection of the nephelometer photo-cell to a 
galvanometer with linear scale allows detection and quantification of 
this light-scattering. Standards are used to set the galvanometer 
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scale to '0' and '100' (arbitrary units), so that comparison with other 
liquids can be made. In these experiments, deionised water was set 
as '0' on the galvanometer scale, and the standard ground perspex 
tube was set as '100'. All further measurements on the 
alginate/propranolol mixtures were made in comparison with these 
standards. 
3.2.2 Materials 
Laminaria hyperborea alginate, BN 902-282-04 (Protan LaboratOries. 
Norway); 
Laminaria hyperborea alginate (non-purified), BN 902-282 (Protan 
LaboratOries, Norway); 
AscophyUum nodosum alginate, BN 911-211-04 (Protan 
LaboratOries, Norway); 
Propranolol hydrochlOride BN 8905237 (CP Pharmaceuticals, 
Loughborough) ; 
Sodium chloride BN 6794910K (BDH, Poole, Dorset); 
EEL Unigalvo Type 200 Nephelometer Head/Galvanometer, E.E.L., 
Halstead, Essex. 
3.2.3 Methods 
A non-purified and a purified (section 3.1.4) alginate from 
Laminaria hyperborea (M:G ratio = 35:65) were used, together with 
an alginate from AscophyUum nodosum (M:G ratio = 61:39, as 
characterised in Chapter 2). These alginates were chosen in order 
to investigate whether the purity of the alginate or its M:G ratio had 
an effect on the interaction with propranolol observed in the 
viscometry experiments. 
Alginate (lgL-1) and propranolol (0 to 0.05M) were mixed in 
various proportions and the turbidity measured in the nephelometer 
relative to the ground perspex standard. The effect on turbidity of 
adding different concentrations of sodium chloride to the 
propranolol/alginate mixtures was also investigated. 
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3.2.4 Results 
Figures 3.5, 3.6 and 3.7 show the results for L. hyperborea 
(non-purified), L. hyperborea (purified) and A. nodosum alglnates 
respectively, and the effect of adding sodium chlOride to the 
propranolol/ alginate mixtures on the concentration of propranolol at 
which precipitation occurs. 
Figure 3.8 shows the effect of added sodium chlOride on the 
visible precipitation point of the propranolol/alginate mixtures for 
the two purified alginates. 
3.2.5 Discussion 
Figures 3.5,3.6 and 3.7 show that increasing the 
concentration of propranolol resulted in a marked increase in 
turbidity, which could be observed in the test mixtures as the 
appearance firstly of a cloudy suspension followed by the formation 
of floccules of a white-coloured precipitate as the concentration of 
propranolol was increased. 
The precipitation point at each concentration of sodium 
chloride was found to be similar for both the non -purified and the 
highly-purified forms of L. hyperborea alginate, which would imply 
that the precipitate was not influenced by the interaction of 
propranolol with contaminants such as phenolic compounds in the 
alginate. In addition, little difference was observed in the 
precipitation point between the high-G L. hyperborea alginate and 
the high-M A. nodosum alginate. This is in marked contrast to the 
interaction of multivalent cations, such as calCium, which interact 
much more strongly with alginate G-blocks than with M -blocks 
(section 1.1.5). 
From Figure 3.8, it can be seen that the addition of sodium as 
a counter-ion suppressed the formation of the precipitate. In 
addition, it was found that if a precipitate was first formed by the 
nloong of propranolol with alginate, this precipitate could be 
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Figure 3.6 Nephelometry of Purified 
L. hyperborea Alginate and Propranolol: 
The Effect of Sodium Chloride 
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Figure 3.7 Nephelometry of Purified 
A. nodosum Alginate and Propranolol: 
The Effect of Sodium Chloride 
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Figure 3.8 The Effect of Sodium Chloride 
on the Visible Precipitation Point of 
Propranolol/Alginate Mixtures 
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re-dissolved by the addition of sufficient sodium ions in the form of 
sodium chlOride solution. The addition of a similar quantity of 
deionised water to the propranolol/ alginate mixtures did not cause 
the precipitate to dissolve. therefore the possibility that the 
precipitate was dissolving merely by a dilution effect was ruled out. 
Studies have been undertaken investigating the affinity of 
alginates for various cations (Smtdsr0d and Haug 1968). These have 
indicated that different ions have different affinities for binding to 
alginates. so that the addition of a counter-ion with a stronger 
binding affinity will result in the displacement of a weaker binding 
species from the alginate. From the experiments undertaken in the 
present studies. the solubilisation of the insoluble propranolol/ 
alginate complex and the release of free propranolol on the addition 
of sodium counter-ions suggests that propranolol has a weaker 
affinity for alginate than sodium. This may be expected if one 
considers the relative molecular bulkiness of the two cations: 
propranolol would suffer greater steric hindrance than sodium ions 
when trying to bind to the alginate. 
However. this system provides a potential mechanism for in 
vivo drug release from the propranolol/alginate complex by 
ion-exchange with simple cations in body fluids. 
3.3 CONCLUSIONS 
An interaction was observed between the alginates L. 
hyperborea or A. ncxl.osum and the model drug propranolol 
hydrochloride. which resulted in the formation of a white-coloured 
preCipitate. This preCipitate could be re-dissolved by the addition of 
sodium (in the form of sodium chlOride) as a counter-ion. 
No difference in the point of precipitation was observed 
between the non-purified and purified forms of L. hyperborea 
alginate. or between the high-G L. hyperborea alginates and the 
high -M A. nodosum alginate. 
In order to quantify the interaction between sodium alginate 
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and propranolol hydrochloride and to investigate the mechanism of 
complex formation, it is proposed to undertake binding studies on 
the purified L. hyperborea and A. nodosum alglnates using 
equilibrium dialysis. These experiments will be described in 
Chapter 4. 
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CHAPTER 4 EQUILIBRIUM DIALYSIS 
AND MOLECULAR MODELLING 
AIMS 
Preliminary viscometry and nephelometry studies (Chapter 3) 
provided direct visual evidence that, above certain concentrations, 
there was an interaction between propranolol and sodium alginate in 
deionised water. The ability of added counter-ions (sodium chlOride) 
to re-dissolve the white precipitate formed suggested that the 
interaction was ionic in nature, possibly a result of ion-pairing 
between the positively-charged drug (Figure 4.1) and the 
negatively-charged polysaccharide (Figure 4.2). 
The objective in this chapter was to quantify this interaction 
in the presence and absence of sodium chloride, under carefully 
controlled conditions using an equilibrium dialysis technique. It was 
intended to investigate the stoichiometry of the interaction and to 
provide evidence of the type of binding from the shape of the 
binding isotherms. In addition, it was hoped that the formation of a 
soluble complex could be identified (in addition to the insoluble 
complex already obseIVed) thereby providing an indication of the 
solubility limit of the propranolol/alginate complex. Before this work 
could be undertaken, the experimental procedure required 
validation in terms of non -specific binding, membrane preparation 
and integrity, and time to reach equilibrium for the system under 
study. 
In addition. we attempted to gain further evidence for the 
nature of the binding by modelling the possible in-vacuo 
three-dimensional structure of the molecular complex using 
computational molecular modelling techniques. 
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Figure 4.1 
Structure of Propranolol Hydrochloride 
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Figure 4.2 
Structure of a Hexose Unit of Alginate 
01111 
11110 ~ O H H
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4.1 INTRODUCTION 
4.1.1 B a c ~ o u n d d
The phenomenon of dialysis was frrst described in 1861 by 
Graham (Graham 1861) and its subsequent evolution has been 
comprehensively reviewed by Carr (1961). 
EqUilibrium dialysis is an application of this general 
phenomenon which is extremely useful for gaining information about 
the extent of binding of ligands to macromolecules and is widely 
used because of its relative simplicity. It is one of several techniques 
available for investigating the interactions of small molecules with 
macromolecules, including, for example, gel permeation 
chromatography, sedimentation in the ultracentrifuge, and 
spectroscopic techniques including NMR. 
EqUilibrium dialysis was first applied to study the binding of 
low molecular weight compounds to biopolymers by Davis (1943). In 
1946, Klotz used the technique to investigate the binding of 
azosulfonic acid with bovine serum albumin. The method, which was 
originally referred to as the 'knotted bag' method, has undergone 
considerable refinement since that time. Attention has focused on 
redUCing the amount of time required to attain equilibrium, and on 
improving the reproducibility of results. For example, the recent 
availability of new and improved membranes has significantly 
speeded up the process, whilst the development of equipment such 
as the 'Dianorm' equilibrium dialyser (described by Weder et al 
1971) enables experimental conditions to be standardised, thereby 
enhancing reproducibility. 
In a typical eqUilibrium dialysis experiment, a solution of a 
macromolecule is separated from a solution of a low molecular 
weight compound (or ligand) by a semi-permeable membrane. All 
species present, except the macromolecule, are able to diffuse freely 
across the membrane. Equilibrium dialysis is based on the prinCiple 
that, if unperturbed, the system will reach eqUilibrium such that the 
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chemical potentials of the ligand are equal on either side of the 
membrane. That is, the activity of the free ligand is equal on both 
sides of the membrane. 
As a fIrst apprOximation, provided dilute solutions are 
employed, the activity of the free ligand may be assumed to be equal 
to its concentration. Therefore, by measuring the fInal free ligand 
concentration, the amount of ligand bound to the macromolecule 
may be determined (see section 4.1.4). 
4.1.2 The 'Dianorm' Apparatus 
In the following binding experiments, the 'Dianorm' 
eqUilibrium dialysis system has been employed. The baSic unit of the 
'Dianorm' apparatus is a Teflon dialysis cell formed from two halves 
(the 'base' and the 'lid'). which are separated by a semi-permeable 
membrane. Each half contains three holes: one for sample 
application; the second acting as an air bleed; and the third for 
emptying of the sample. The cells are mounted in groups of five in a 
cell-carrier, each cell being separated by a spring-loaded spacer 
which acts as a sealing mechanism (Figure 4.3) Each group can then 
be attached to the carrier unit for rotation in a water bath at 
controlled temperature. The apparatus contains a total of twenty 
cells. The solution of drug is injected into one half-cell and the 
polymer solution into the other. The membrane is selected such 
that the drug can diffuse freely across it, whilst the polymer is 
completely retained. 
The 'Dianorm' apparatus has been designed so that 
standardised reproducible eqUilibrium dialysis experiments can be 
performed for up to twenty samples simultaneously. The system has 
several other advantages over conventional bag dialysis: 
(1) A high concentration gradient is maintained across the 
membrane, since mixing (by slow rotation at 4-20 r.p.m.) is 
continuous, therefore shorter dialysis times are required; 
(il) Smaller sample volumes can be used (approximately 3mL 
for the experiments described in section 4.3); 
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Figure 4.3 
Diagrammatic Representation of a 
'Dianorm' Cell Unit 
/ t \ 2 3 f 
1 5 
1. Driving flange. 
2. Teflon cell BASE ) 
Five pairs in complete stack 
3. Teflon cell LID ) 
4. Spring loaded cell spacers (Six in complete stack). 
5. Bearing flange secured with three knurled nuts. 
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(iii) The experiments may be carried out at any temperature 
between OOC and 60oC. Rapid heat exchange between the water bath 
and the cell contents occurs because the cell walls are relatively thin 
(Weder et al 1971); 
(Iv) The filling and emptying of the cells is easily performed 
using Eppendorf/Gilson type pipettes; 
(v) Recovery of samples after dialysis approaches 1000/0. 
4.1.3. Membranes for Equilibrium Dialysis 
It is a prerequisite that the membrane chosen for a particular 
equilibrium dialysis experiment must allow free passage of the 
ligand but not the macromolecule. and should not bind either the 
ligand or macromolecule to any appreciable extent. Compliance with 
these reqUirements must be ascertained prior to any dialysis 
experiments. 
Transport of the ligand through the membrane obeys Fick's 
First Law of Diffusion such that the rate of diffusion depends upon 
the surface area of the membrane. the concentration gradient and 
the diffusion coeffiCient. (The diffusion coefficient is a function of 
temperature and a characteristic of the particular ligand molecule). 
Membranes which are commonly used in equilibrium dialysis 
experiments include Visking. Spectrapor and Nucleopore. These 
vary in the material from which they are made (usually cellulose or 
polycarbonate). their permeability (related to pore size and 
membrane thickness). and their molecular weight cut-off pOints. 
Preference is normally given to membranes which fulfIl the above 
requirements. but which give rise to the most rapid dialysis times. 
4.1.4 General Theory of Bindine 
ConSider the reverSible binding of a ligand L to a macromolecule A: 
A + L ~ ~ AL 
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with the equilibrium constant (K) for this association given by: 
K = 
[AL] 
[A].[L] 
It is also convenient to refer to a 'dissociation constant' (KcJ) 
which is merely the reciprocal of the above association constant: 
K<f = 
[A].[L] 
[AL] 
(Equation 4.1) 
The number of moles L bound per mole of A. under a given set 
of conditions may be defined as 'r' (the 'binding parameter'), where: 
r -
r -
concentration of L bound to A 
total concentration of all forms of A 
[AL] 
[A]+[AL] 
From Equation 4. 1 : 
[AL] -
[A].[L] 
KcJ 
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So that: 
( [ A ] [ L ] ) / ~ ~
r = 
[A]+([A][L]) / ~ ~
That is: 
[ L] 
r = (Equation 4.2) 
~ ~ + [L] 
So far, only the case where one mole of a ligand (L) is bound 
by an individual site on a macromolecule (A) has been considered. 
However, it is possible that several moles of L may be bound by A. 
Equation 4.2 (above) was derived for a single binding site. For 
the case where one mole of A can bind up to n moles of L, this 
equation is modified: 
n[L] 
r - (Equation 4.3) 
~ ~ + [L] 
where the n sites are assumed to be equal and independent (that is, 
the free energy of binding is the same for each site). ~ ~ is now an 
average dissociation constant. 
This fundamental equation can be rearranged into two main 
forms suitable for graphical treatment: 
(1) By taking the reciprocal of each side of the equation: 
1 1 ~ ~
+ (Equation 4.4) 
r n n[L] 
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so that a plot of l/lL) versus llr gives a straight line of slope 
Kct/n and an intercept on the y axis of lin. This is known as the 
Double Reciprocal plot. 
(it) An alternative arrangement is: 
r n r 
(Equation 4.5) 
lL) K<f K<f 
so that a plot of r versus rilL) gives a straight line of slope 
-l/Kct and an intercept on the x-axis of n. This is known as the 
Scatchard equation. 
4.1.5 Analysis of Experimental Results from the 'Dianorm' Apparatus 
The amount of time required to reach equilibrium is referred 
to as the 'dialysis time'. When this has elapsed. an equilibrium 
situation is attained so that the concentration of the free ligand 
(CL(O) is the same in both compartments of the cell. In the 
compartment containing no polymer. the free ligand concentration 
can be determined using a suitable analytical technique (in this case 
UV spectroscopy). The other compartment contains the bound plus 
the free ligand (CL(O + CL(b))' Since the start concentration of the 
ligand (CL(O)) and the concentration of the polymer (CA) are known. 
the amount bound to the polymer can be easily calculated according 
to the following relationship: 
CL(O) = 2CUO + CUb) (Equation 4.6) 
In some cases. it is found that the ligand binds to the 
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membrane or to the dialysis apparatus. However. this 'non-specific 
binding' can be quantified in a validation experiment and a 
correction factor introduced if necessary as follows: 
(Equation 4.7) 
where CL(m) is the concentration of ligand bound to the membrane 
or dialySis apparatus. 
Using the nomenclature in section 4.1.4: 
CL(b) / CA = r 
and CL(f) = L. 
Thus. the experimentally determined values 'r' and 'CL(f)' may 
be used to present the binding data as: 
(1) Binding isotherms. that is. plots of 'r' versus [L]; 
(11) Scatchard plots; 
(iii) Double Reciprocal plots. 
These plots enable several parameters to be determined. 
including n. the number of binding sites on the alginate available for 
binding to propranolol. It is also possible to determine whether or 
not positive or negative co-operative binding is occurring (section 
4.5). 
4.2 MATERIALS AND EQUIPMENT 
'Dianorm' eqUilibrium dialyser (Dianorm-Gerate. Germany); 
Uvikon 860 UV Spectrophotometer. Kontron Instruments. England; 
Visking dialysis tubing (cut-off point 5.000 Daltons); 
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Laminaria hyperborea alginate, BN 902-282-04 (Protan laboratories. 
NOIWay); 
AscophyUum nodosum alginate, BN 911-211-04 (Protan 
laboratories, NOIWay); 
Propranolol hydrochloride BN 8905237 (CP Pharmaceuticals, 
Loughborough) ; 
Sodium chlOride BN 6794910K (BDH, Poole, Dorset); 
AnaLar deionised water BN 3137510L (BDH, Poole, Dorset). 
All were used as received. 
4.3 VALIDATION EXPERIMENTS 
EqUilibrium dialysis techniques rely on the prinCiple that the 
ligand under investigation will penetrate the membrane easily but 
that the macromolecule will be retained on one side of the 
membrane, and that the ligand will not bind significantly to the 
dialysis apparatus. Therefore, the following validation experiments 
were carried out prior to the binding experiments: 
(i) suitability of the Visking membrane (verification of its 
ability to retain sodium alginate solution and to allow the free 
passage of propranolol hydrochloride); 
(ii) determination of the time required to reach equilibrium 
for the propranolol/ alginate system employed; 
(iii) investigation of the non -specific binding of propranolol to 
the 'Dianorm' apparatus; 
(iv) investigation of the non -specific binding of alginate to the 
'Dianorm' apparatus. 
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4.3.1 Verification of the ability of the membrane to retain sodium 
a l ~ n a t e e in a dialysis cell half 
4.3.1.1 Methods 
The following preparation procedure was undertaken prior to 
all experiments: 
The membrane was cut into discs slightly larger than the 
dialysis cells. These were boiled for 30 minutes in deionised water. 
then soaked for three periods of 30 minutes in deionised water. 
After the third soak, the membranes were transferred to the 
experimental solution (either deionised water or sodium chloride) 
for two final soakings of 15 minutes each. Any reSidual solution was 
carefully removed with filter paper before placing the disc between 
the Teflon cells using plastic tweezers. 
Prior to loading, the Teflon cells were cleaned thoroughly 
using a 5%v Iv Decon solution and rinsed several times in deionised 
water, then dried at room temperature. 
The dialysis cells were filled as follows: 
Test cells: 
BASE: 3mL sodium alginate solution (2gL-l or 4gL-l in 
deionised water). 
LID 3mL deionised water. 
Control cells: 
BASE 3mL deionised water. 
LIDS : 3mL deionised water. 
Temperature: 25.00 C. 
Dialysis time: 72 hours. 20 rotations per minute. 
Membrane: Vlsking. cut-off point (nominal) 5000 Daltons. 
After dialysis, a ImL sample from the lids of the dialysis cells 
was subjected to the phenol-sulphurtc acid test (DubOis et al 1956) 
as described in section 2.2.5.1. 
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4.3.1.2 Results 
Tables 4.1 and 4.2 show the results after subjecting the 
membrane to the preparation procedure described above (4.3.1.1). 
Table 4.1 Verification of the abili1y of the semi-penneable 
membrane to retain sodium a l ~ i n a t e e in a dialysis cell half 
Laminaria huperborea alginate 2gL-1 
TEST CELLS 
Sample 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
UV Abs. 
(480nm) 
0.021 
0.036 
0.012 
0.014 
0.039 
0.015 
0.022 
0.026 
0.008 
0.014 
CONTROL CELLS 
Sample 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
UV Abs. 
(480nm) 
0.005 
0.009 
0.027 
0.032 
0.034 
0.022 
0.033 
0.016 
0.007 
0.013 
Mean = 0.021 Mean = 0.020 
SD = 0.009 SO = 0.01 
-99-
Table 4.2 Verification of the ability of the semi-permeable 
membrane to retain sodium a l ~ i n a t e e in a dialySis cell half 
Laminaria hyperborea a l ~ i n a t e e 4 ~ L - l l
TEST CELLS CONTROL CELLS 
Sample UV Abs. Sample 
(480nm) 
1 0.031 1 
2 0.027 2 
3 0.009 3 
4 0.013 4 
5 0.016 5 
6 0.033 6 
7 0.026 7 
8 0.021 8 
9 0.015 9 
10 0.020 10 
UV Abs. 
(480nm) 
0.028 
0.031 
0.017 
0.009 
0.007 
0.018 
0.030 
0.016 
0.010 
0.029 
Mean = 0.021 
SD = 0.008 
Mean = 0.0195 
SD = 0.009 
The results for the alginate test cells compare favourably with 
the control cells containing only deionised water. This indicates that 
Laminaria hyperborea alginate is retained by the membrane in one 
dialysis half-cell and gives confidence in the preparation and 
cell-assembling procedure, in that the membrane appears to remain 
intact. 
A small amount of saccharide was detected in both the 
control cells and in the test cells by the phenol-sulphuric acid test. 
However, this test is not specific for uronic acids, but is a general 
test for simple sugars, oUgosaccharides and polysaccharides. It is 
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therefore possible that this was a result of material leaching from 
the cellulose membrane into both the control and the test solutions, 
as the effect was found to be greatly reduced by washing the 
membrane. The membrane preparation procedure described above 
was therefore employed in all future experiments. 
4.3.2 Investi4ation of the time required to reach equilibrium for a 
propranolol/a1ltinate system and verification of the p a s s ~ e e of 
propranolol across the semi-permeable Viskine membrane 
The dialysis time must be determined for each individual 
ligand which will be used in dialysis experiments, in order to ensure 
that the system has reached equilibrium before the cell contents are 
analysed. Thus. for the purpose of these experiments. it was 
necessary to determine the dialysis time for propranolol 
hydrochloride (MW = 295.8 Daltons) in the presence of Laminaria 
hyperborea alginate. 
4.3.2.1 ~ e t h o d s s
The dialysis cells were filled as follows: 
BASE: 3mL propranolol solution (O.OIM or O.IM) 
LID : 3mL deionised water or alginate solution IgL -1. 
Temperature: 25.0oC. 
Dialysis time: 8 hours. 20 rotations per minute. 
Membrane: Visking. cut -off point (nominal) 5000 Daltons. 
Dialysis of a known concentration of propranolol against 
deionised water was performed under the same conditions as those 
proposed for the subsequent binding experiments (that is, 
temperature 25.0oC; 20 rotations per minute; Visking membrane 
with cut-off point at approximately 5000 Daltons). The change in 
concentration of propranolol in both half-cells was determined as a 
function of time until equilibrium was attained. Propranolol 
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concentration was determined spectrophotometrically using a 
Kontron Uvikon UV spectrophotometer at wavelength 288nm. 
These experiments were repeated in the presence of 
Laminaria hyperborea alginate in order to ensure that the presence 
of the alginate did not significantly increase the time to reach 
equilibrium. 
4.3.2.2 Results 
Figures 4.4 and 4.5 show the results for propranolol 
concentrations of 0.1 M and O.OIM respectively. Equilibrium is 
reached at the point where the two curves asymptote the line at 
approximately 500/0 of the starting concentration. Figure 4.6 shows 
the results for propranolol O.IM in the presence of alginate 1.0gL-l. 
Thus, in each case, under the conditions outlined above, 
eqUilibrium was attained in approximately 3-4 hours. In subsequent 
experiments the dialysis time was set at 5 hours or greater to 
ensure that eqUilibrium had been reached. 
These results also demonstrate that propranolol 
hydrochloride (MW = 295.8 Daltons) passes freely through the 
proposed dialysis membrane (cut-off point 5000 Daltons). as 
expected. 
4.3.3. I n v e s ~ a t l o n n of non-specific bindine of propranolol 
hydrochloride to the Dianorm equilibrium dialysis apparatus 
In any eqUilibrium dialysis experiment, there is a possibility 
that the experimental ligand may bind to the membrane or the 
apparatus, resulting in a decrease in available free ligand. Therefore, 
it is necessary to quantify this 'non-specific' binding before 
proceeding with the actual equilibrium dialysis experiments. 
Depending on the degree of non-speCific binding. it may either be 
considered negligible in comparison to experimental binding. or 
require a correction to be made to the results of binding 
experinlents. 
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Figure 4.4 Detennination of Time to Reach 
Equilibrium in the 'Dianonn' Equilibrium 
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Figure 4.5 Determination of Time to Reach 
Equilibrium in the 'Dianonn' Equilibrium 
Dialyser. Propranolol Concentration O.OIM 
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4.3.3.1 Methods 
The dialysis cells were filled as follows (five samples for each 
concentration of propranolol): 
BASE: 3mL propranolol solution (O.OOlM, O.OlM, O.lM or 
0.5M) 
LID : 3mL deionised water. 
Temperature: 25.00 C. 
Dialysis time: 24 hours, 20 rotations per minute. 
Membrane: Visking, cut-off point (nominal) 5000 Daltons. 
After dialysis, 2mL samples from both compartments of each 
sample cell were analysed at 288nm in a Kontron Uvikon UV 
spectrophotometer for the presence of propranolol. Any loss of 
propranolol during the dialysis experiments was assumed to be due 
to non-specific binding to the 'Dianorm' apparatus. 
4.3.3.2 Results 
Table 4.3 shows the results obtained. 
Table 4.3 Investiflation of non-specific bindinli! of propranolol 
to the 'Dianorm' apparatus. 
Start Conc. Final Conc. Final Conc. Loss of 
Propranolol Propranolol Propranolol Propranolol 
1Ml in Base (M) in Lid (M) due to Non-
Specific 
Binding (0/0) 
0.001 5 x 10-4 4.9 x 10-4 1 
0.01 0.0050 0.0050 o 
0.1 0.0495 0.0500 0.5 
0.5 0.2500 0.2470 0.6 
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These results indicate that over a wide concentration range 
the degree of non -specific binding is negligible ( ~ ~ 10/0) in 
comparison to the amount of available free propranolol. Thus. for 
these experiments, there was no need for a correction factor to be 
applied when determining binding constants for propranolol/ 
alginate systems at these concentrations. 
4.3.4. Investliation of non-specific bindine of sodium ~ t e e to the 
Dianorm equilibrium dialysis apparatus 
As for the previous experiments to determine the 
non-specific binding of propranolol to the Dianorm apparatus (4.3.3) 
it was also necessary to quantify any non-specific binding of sodium 
alginate. 
4 . 3 . 4 . 1 . ~ e t h o d s s
The dialysis cells were filled as follows: 
BASE: 3mL sodium alginate solution (lgL-1. 2gL-1 or 
4gL -1 in deionised water). 
LID 3mL deionised water. 
Temperature: 25.00 C. 
Dialysis time: 72 hours, 20 rotations per minute . 
• 
Membrane: Visking. cut-off point (nominal) 5000 Daltons. 
Mter dialysis, a 1mL sample from both compartments of the 
dialysis cells was subjected to the phenol-sulphuric acid test (DubOis 
et al 1956) as described in section 2.2.5.1. Any loss of alginate 
during the dialysis experiments was assumed to be due to 
non-specific binding to the Dianorm apparatus. 
4.3.4.2 Results 
Table 4.4 shows the results obtained. 
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Table 4.4 I n v e s t i ~ a t i o n n of non-specific b i n d i n ~ ~ of sodium 
a l ~ n a t e e to the 'Dianorm' apparatus. 
Start Conc. Final Conc. Final Conc. Loss of 
Alilinate Alllinate A l ~ i n a t e e A l ~ i n a t e e
~ - 1 1 1 in Base ( ~ L L-11 in Lid ( ~ L - l 1 1 due to Non-
Specific 
B i n d i n ~ ~ (0/0) 
l.0 0.99 0.01 0 
2.0 l.97 0.01 1 
4.0 3.97 0.02 0.25 
These results indicate that, over a range of concentrations, 
the amount of non-specific binding of alginate was negligible ( ~ ~ 10/0). 
Thus, for these experiments, there was no need for a correction 
factor to be applied when determining binding constants for 
propranolol/ alginate systems at these concentrations. 
4.3.5 Conclusions 
The time required to reach eqUilibrium using the 'Dianorm' 
eqUilibrium dialysis apparatus for a propranolol and a 
propranolol/ alginate system was of the order of 3-4 hours. 
The membrane chosen (Visking, nominal cut-off point 5000 
Daltons) was found to be suitable for the propranolol/alginate system 
to be studied since it allowed free passage of propranolol 
hydrochloride solution. but retained sodium alginate solution in a 
dialysis cell-half. 
The 'Dianorm' apparatus was found to be suitable for the 
propranolol/alginate system to be studied, since the non-specific 
binding of propranolol hydrochloride in the 'Dianorm' apparatus was 
found to be negligible. 
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4.4 METHODS 
4.4.1 Bindlna experiments 
The dialysis membrane used in these experiments was 
Visking tubing with a cut-off point of 5000 Daltons. The validation 
experiments (section 4.3) showed that preparation of the membrane 
was essential to eliminate adherent impurities which could interfere 
with the subsequent binding experiments. The preparation 
procedure described in section 4.3.2.2 above was therefore 
undertaken prior to all experiments. 
The dialysis cells were assembled by sandwiching a disc of 
pre-treated semi-permeable membrane (see section 4.3.3) between 
two half-cells. Five cells were then mounted in a cell-carrier. and 
four assembled carriers moun ted in a rotating drive unit. in a water 
bath at 250 C + 0.50 C. 
The cells. each with a half-cell volume of 5mL. were filled 
with 3.OmL of propranolol hydrochloride solution in one half. and 
3.0mL of alginate solution in the other. using a Gilson pipette. The 
2mL void space ensures adequate mixing of the solution and good 
membrane contact for the duration of the experiment. 
Mter each dialysis run. the solution on the alginate-free side 
of the cell was drained. and the concentration of free propranolol 
determined spectrophotometrically at 288nm. 
The following experiments were carried out: 
(1) The binding of propranolol to Laminaria hyperoorea alginate 
(lgL-l ); 
(H) The binding of propranolol to AscophyUum nodosum alginate 
(lgL-l) 
(Hi) The effect of sodium chloride on the binding of propranolol 
to each alginate. 
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4.4.2 Molecular Modelline 
The possible in vacuo three-dimensional structure of a 
propranolol/ alginate complex was investigated using the 'COSMIC' 
(COmputation and Structure Manipulation In Chemistry) Molecular 
Modelling System (Vinter et al 1987). This is a molecular graphics 
and computational chemistry framework which has been designed 
primarily to handle small molecules of up to 300 atoms and which 
has evolved as a molecular modelling aid for use in the 
pharmaceutical industry. 
The propranolol and alginate molecules were first sketched 
freehand using the 'COSMIC' system, then the charges on each of 
the atoms were calculated using the programme 'Charge 2' 
(Abraham and Smith 1988). The two molecules were then allowed 
to dock together using the 'single hard sphere' docking method 
deSCribed by Vinter et al (1987). The 'Cosmic Force Field' 
programme (Morley et al 1991) (which calculates the energy of a 
molecule given a certain geometry) was used to 'minimise' the 
structure, that is, to calculate the structure which has the lowest 
energy. 
In summary, the 'stationary' molecule is placed at the centre 
of a loA sphere and the 'mobile' molecule is placed in tum at pOints 
on the sphere about 1A apart, a total of 204 starting pOints. At each 
starting point, the mobile molecule is rotated about its centre in 60° 
steps about all three axes, and the lowest energy obtained defmes 
the starting orientation for a subsequent simplex energy 
minimisation. Each molecule is treated as a rigid body, and no 
relaxation of bond lengths, angles or torsional angles is allowed. The 
simplex runs for a maximum of 500 iterations, or until the change in 
energy between successive iterations is less than 0.0001 kcal/mole. 
All 204 final positions of the mobile molecule are stored by the 
computer. The photographs obtained show the lowest energy 
complex of the 204 that are produced by the docking routine 
described above. 
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4.5 RESULTS 
Figures 4.7 and 4.8 show the binding isotherm (CUt) vs. r) for 
the binding of propranolol to L. hyperborea alginate and A. nodosum 
alginate respectively in distilled water. 
The Scatchard equation and the Double Reciprocal equation 
(section 4.1.4) were used to determine the binding parameters 
discussed in section 4.1.4 above. Figures 4.9 and 4.10 show a 
Scatchard plot and a Double Reciprocal plot for L. hyperborea 
alginate, and Figures 4.11 and 4.12 show the same plots for A. 
nodosum alginate. (Note that the curves through the pOints for 
Figures 4.9 to 4.12 were fitted by eye and are therefore for guidance 
only, in order to show the general trend of the plots). 
Figures 4.13 and 4.14 illustrate the influence of sodium 
chloride on the binding of propranolol (O.OOlM and 0.02M 
respectively) to the two alginates (1 gL -1). 
Figure 4.15 shows the possible in vacuo three-dimensional 
structure of the propranolol/alginate complex as modelled using the 
'COSMIC' Molecular Modelling System. (Oxygen is represented in 
red and nitrogen in blue). 
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Figure 4.14 The Effect of Added Sodium 
Chloride on the Binding of Propranolol to 
L. hyperborea and A. nodosum alginates 
(Initial Propranolol Concentration O.02M) 
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Figure 4.15 
The Possible In Vacuo Three-Dimensional 
Structure of a Propranolol/Alginate 
Complex as Modelled using the 'COSMIC' 
Molecular Modelling System. 
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4.6 DISCUSSION 
The type of binding occurring in a given system can generally 
be recognised from the saturation curve ('binding isothenn') and 
may be confinned by the use of Scatchard or Double Reciprocal 
plots. As indicated by Equations 4.4 and 4.5, the Scatchard plot and 
the Double Reciprocal plot would be expected to yield straight lines 
for hyperbolic binding. However. it sometimes happens that these 
binding plots do not yield straight lines but instead are curved. This 
reflects the fact that hyperbolic binding is not occurrtng and that 
the ligand sites on the macromolecule are not equivalent. 
For example, in the case of oxygen binding to haemoglobin. it 
is found that the saturation curve is sigmoid in shape. This is 
because haemoglobin consists of four sub-units held together by 
non-covalent bonds. Haemoglobin is said to show 'positive 
co-operativity', that is. binding of the first oxygen molecule 
enhances the binding of the subsequent ones. The opposite of the 
'positive co-operativity' phenomenon is that of 'negative 
co-operativity', where the binding of the first ligand molecule 
discourages binding of subsequent ones. This is thought to occur in 
the binding of NAD+ to rabbit muscle glyceraldehyde-3-phosphate 
dehydrogenase (Price and Dwek 1979). 
Two main theories exist to account for the different types of 
binding (Price and Dwek 1979). Both stress the importance of 
changes in shape and confonnation of a macromolecule associated 
with the binding of a ligand. The 'concerted' theory of Monod, 
Wyman and Changeux is based on the proposition that when a ligand 
binds to one sub-unit (for example. the hexose residue of an 
alginate) in a multi-sub-unit macromolecule, all the sub-units change 
their shape in a 'concerted' fashion. In the 'sequential' model of 
Koshland, Nementhy and Filmer, the confonnational changes are 
thought to be sequential. that is, the ligand changes the 
conformation of only the sub-unit to which it binds. This 
confomlational change then alters the interaction(s) between the 
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sub-unit and its neighbouring sub-units making the binding to the 
latter either stronger or weaker. It should also be remembered that 
the ligand binding sites on certain macromolecules may be 
non -equivalent even in the absence of ligands, which could result in 
non -hyperbolic binding in the presence of a ligand. 
Typical saturation curves for hyperbolic binding, positive 
co-operativity and negative co-operativity are illustrated in Figure 
4.16. However, it can be seen from Figure 4.16 that it can be 
difficult to distinguish between curve 1 (hyperbolic binding) and 
curve 3 (negative co-operativity). For this reason, a Scatchard plot 
and/ or a Double Reciprocal plot are useful in elucidating the type of 
binding that may be occurring and also for the determination of 'n', 
the number of binding sites. Figure 4.17 illustrates a typical Double 
Reciprocal plot for each of the three forms of binding, whilst Figure 
4.18 shows the type of Scatchard plot obtained for each. 
From the shape of the binding isotherms for the binding data 
from the experiments undertaken in this study (Figures 4.7 and 4.8, 
for the binding of propranolol to L. hyperborea and A. nodosum 
alginates respectively), it could be inferred that the type of binding 
was either hyperbolic or negative co-operativity. If hyperbolic 
binding was occurring, it would be expected that a Scatchard plot 
and a Double Reciprocal plot would yield a straight line. However, as 
can be seen from Figures 4.9 to 4.12, this was not the case. 
Thus, comparing the results obtained in Figures 4.9 to 4.12 
with the example plots illustrated in Figure 4.16 to 4.18, it would 
appear that negative co-operativity is occurring when propranolol 
binds to alginate. This means that the binding of one propranolol 
molecule to a hexose unit on the alginate makes it more difficult for 
subsequent propranolol molecules to bind. It is possible to 
detennine 'n', the number of binding sites on the alginate for 
binding of propranolol. From extrapolation of the curves in Figures 
4.9 to 4.12, 'n'=l. This indicates that one propranolol molecule 
binds with one hexose residue from the alginate. This is in keeping 
with the chemical structures of propranolol and alginate, since an 
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Figure 4.16 
Saturation Curve 
Figure 4.17 
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ionic interaction is possible between the positively-charged tertiary 
amine group of propranolol (Figure 4.1) and the negatively-charged 
carboxyl group on each hexose unit of the alginate (Figure 4.2). 
Molecular modelling was carried out in order to try to 
visualise the interaction between alginate and propranolol in vacuo 
and in particular to try to discover why negative co-operativity was 
occurring. From Figure 4.15. if the carboxyl group on the alginate 
interacting with the tertiary amine group on the propranolol is 
modelled. it would appear that the presence of a propranolol 
molecule interacting with the carboxyl group would make it 
stereochemically difficult for another propranolol molecule to bind 
to the adjacent carboxyl group. 
However. the molecular model shown in Figure 4.15 does not 
take into account the aqueous environment in which the binding 
experiments were carried out, and it is postulated that, in the 
presence of water. the alginate molecules would be much more 
extended than those shown. thereby theoretically allowing a 
propranolol molecule to bind to every carboxyl group on the alginate. 
Thus. at the saturation point, it is possible that each carboxyl group 
on the alginate is interacting with the tertiary amine group of one 
propranolol molecule. in keeping with the 'one-to-one binding' 
(where 'n' = 1) described above. However, the negative 
co-operativity observed in the dialysis experiments might be 
expected. due to steric hindrance from the large naphthalene group 
on the propranolol molecules making it difficult for further 
propranolol molecules to bind to adjacent alginate carboxyl groups. 
A major point to note is that no difference was observed in 
the binding of propranolol to the high-G alginate. L. hyperborea, 
(M:G ratio = 35:65) compared to its binding with the high-M 
alginate. A. nodosum (M:G ratio = 61 :39). This is in contrast to the 
interaction of alginate with. for example, calcium ions. where the 
interaction is much stronger with an alginate rich in guluronic-acid. 
resulting in the formation of strong alginate gels (Chapter 1). This 
indicates that propranolol appears to have the same affinity for 
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binding to G-blocks as to M -blocks or mixed M -G blocks and for this 
reason, in the in vitro and in vivo experiments which follow, only 
the high-G alginate, LaminaJia hyperborea was studied. 
Figures 4.13 and 4.14 demonstrate the effect of added 
sodium chloride on the binding of propranolol (O.001M and O.02M 
respectively) to alginate (lgL-1). As the concentration of sodium 
chloride is increased, the binding of propranolol to the alginate is 
gradually decreased, until at a concentration of O.25M sodium 
chlOride all the propranolol on the alginate has been replaced by 
Na+ ions and all the precipitate has disappeared. The fact that the 
Na+ ions are able to displace propranolol from an alginate complex 
provides a possible mechanism for controlled release of propranolol 
in vivo. Many body flUids, for example nasal secretions, contain 
sodium ions, together with other positive counter-ions such as 
calcium and magnesium. If the propranolol was administered as an 
insoluble complex with alginate (for example, as a suspension) it can 
be seen that any counter-ions present could diffuse in and release 
propranolol from the alginate, with the pOSSibility of controlled 
release if the process is sufficiently slow. The following chapters will 
investigate this possibility for nasal delivery of propranolol. 
4.7 CONCLUSIONS 
The interaction between propranolol and alginate is thought 
to be ionic in nature, with the positively-charged tertiary amine 
group on the propranolol molecules interacting with the 
negatively-charged carboxyl group on each hexose residue of the 
alginate molecule. The results from the binding experiments 
indicated that, at the saturation pOint, stoichiometric 'one-to-one' 
binding was taking place, with one propranolol molecule bound to 
one carboxyl group on each hexose unit of the alginate chain. 
Analysis of the binding isotherm before saturation indicated that 
'negative co-operativity' was occurring, such that the presence of 
one propranolol molecule binding to a carboxyl group on the alginate 
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made it more difficult for subsequent propranolol molecules to bind 
to adjacent carboxyl groups. 
No difference in the degree of binding of propranolol to the 
Wgh-G or Wgh-M alginate was observed. in marked contrast to the 
interaction of alginate with. for example. calcium ions. where the 
interaction is much stronger with a high-G alginate. 
Molecular modelling was carried out in an attempt to visualise 
the possible three-dimensional structure of the ionic complex 
formed between propranolol and alginate. The theoretical model 
produced supported the experimental finding that negative 
co-operativity was occurring. since it demonstrated that the binding 
of the relatively 'bulky' propranolol molecule to the alginate would 
make it stereochemically difficult for subsequent propranolol 
molecules to bind to carboxyl groups on adjacent hexose residues. 
The interaction and formation of an insoluble propranolol/ 
alginate complex could be reversed by the addition of sodium 
counter-ions. which displace the propranolol from the alginate and 
dissolve the complex by the formation of soluble sodium alginate. 
This should provide a mechanism for controlling the release of 
propranolol in vivo and it is proposed to investigate it further. 
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CHAPTER 5 PREPARATION AND 
CHARACTERISATION OF A 
PROPRANOLOL/ALGINATE COMPLEX 
5.1 INTRODUCTION 
In order to prepare a dosage form which could be 
conveniently administered to rats, it was decided to prepare a dried 
alginate/propranolol complex which could then be reconstituted. 
Several techniques for achieving this were investigated, including 
filtration and oven drying, but these resulted in either loss of the 
preCipitate during preparation, or the formation of a charred brown 
complex. 
The technique eventually chosen for preparation of the 
dosage form was freeze-drying. The following chapter describes the 
formation of a freeze-dried propranolol/alginate complex which was 
characterised in terms of particle-size, propranolol content and 
drug release in vitro in the presence of sodium chloride ions. 
5.2 FORMATION OF THE COMPLEX 
5.2.1 Introduction 
The ratio of propranolol to alginate used in preparing the 
preCipitate was determined using the results obtained from the 
equilibrium dialysis experiments deSCribed in Chapter 4. A point on 
the plateau of the binding isotherm plot for Laminaria hyperoorea 
alginate (Figure 4.2) where 1000/0 of the alginate hexose reSidues 
were occupied by propranolol ions ('one-to-one' binding) was 
chosen. The concentration of alginate at this point was 19L-1 and 
the concentration of propranolol was 0.02M. 
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5 . 2 . 2 ~ t e r i a l s s
Propranolol hydrochlOride BN 8905237 (CP Pharmaceuticals, 
Loughborough) : 
Laminaria hyperborea alginate BN 902-282-04 (Protan laboratories, 
Norway): 
AnaLar water BN 3137510L (BDH, Poole, Dorset). 
All were used as received. 
5.2.3 Methods 
A propranolol/ alginate complex was prepared as follows: 
Alginate solution (500mL: 2gL-l) was mixed with propranolol 
solution (0.04M) to produce a cloudy mixture, which was stirred for 
45 minutes at 250 C, and then left to allow the preCipitate to settle. 
The supernatant was carefully poured off, and the slurry-like 
preCipitate centrifuged at 3000 r.p.m. for 5 minutes. Further 
supernatant was poured off and analysed in a UV spectrophotometer 
at 288nm for propranolol content. The preCipitate was then washed 
with deionised water to remove any free propranolol and soluble 
propranolol/alginate complex, then re-centrifuged. This washing 
and centrifugation procedure was repeated five times until the UV 
analysis of the supernatant indicated that the concentration of 
propranolol in the supernatant was negligible. 
After the final washing, the slurry was centrifuged at 3000 
r.p.m. for 30 minutes and excess water removed with a pipette. The 
complex was then transferred to a 100mL round -bottomed flask and 
frozen in situ in liqUid nitrogen. It was then freeze-dried at -600 C 
for 24 hours. 
5.2.4 Results 
A white 'spongy' freeze-dried complex of alginate and 
propranolol was produced, which was characterised as deSCribed in 
section 5.3. 
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5.3 CHARACTERISATION OF THE PROPRANOLOL/ALGINATE 
COMPLEX 
The freeze-dried complex was characterised in terms of: 
(1) particle size in suspension (section 5.3.1); 
(ii) propranolol content (section 5.3.2); 
(iii) in vitro drug release (section 5.3.3). 
5.3.1 Particle Size in Suspension 
5.3.1.1 Introduction 
Measurements of the particle Size of drugs are made routinely 
in the pharmaceutical industry. Particle size can have an important 
effect on the dissolution rate of a drug, since any reduction in 
particle size has the effect of exposing increasing amounts of surface 
of the drug to the solvent. In vivo, this may determine the rate of 
absorption of a drug. the speed of onset of effect of the drug, the 
duration of therapeutic response and the occurrence of toxic 
side-effects (Florence and Attwood 1985). 
For a spherical particle, it is possible to describe particle size 
in tenns of diameter, but this becomes ambiguous if the particle is 
irregular in shape. For this reason, the particle size of a 
non -spherical particle is quoted as the diameter of a sphere which 
is in some way equivalent to that particle. Such a sphere is termed 
an 'equivalent sphere' and the diameter is an 'equivalent diameter', 
In these experiments. the particle size is expressed as the 'volume 
equivalent diameter' (dv). This means that if an irregular particle is 
quoted as having a volume equivalent diameter of, say. 1 
micrometre. it has the same volume as a spherical particle of 
diameter 1 micrometre (Washington 1992). 
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5.3.1.2 Materials and Equipment 
Propranolol/alginate complex (section 5.2 above); 
Sodium chloride BN 6794910K (BDH, Poole, Dorset); 
AnaLar water BN 3137510L (BDH, Poole, Dorset); 
Malvern Mastersizer particle sizer, Malvern Instruments, Malvern. 
England. 
All reagents were used as received. 
5.3.1.3 Methods 
The freeze-dried propranolol/alginate complex was prepared 
as in section 5.2. This was re-suspended in AnaLar deionised water 
by shaking for five minutes by hand and the particle size range of the 
suspension was determined using a Malvern 'Mastersizer'. 
The reader is referred to Washington (1992) for a detailed 
description of the Malvern Mastersizer and its use in determining 
particle size. In summary, the technique involves passing a beam of 
light from a laser source through the sample which is stirred 
continuously to keep the particles in suspension. Light scattered by 
the sample passes onto a detector and the use of computer software 
enables the calculatlon of a particle size distribution from this 
scattering pattern. 
5.3.1.4 Results 
Figures 5.1 and 5.2 show the particle size distributlon and the 
cumulative particle size distributlon respectively for the freeze-dried 
propranolol/ alginate complex re-suspended in AnaLar deionised 
water. 
Using the computer attached to the Mastersizer. it was 
calculated that the average size of the propranolol/ alginate complex 
particles in suspension was 22.5J,!m (volume equivalent diameter). 
800/0 of particles in the sample were within the size range 4.611n1 to 
82Jlnl; 100/0 of particles were larger than 82.0J,!m and 100/0 of 
particles were smaller than 4.6J,!m. 
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Figure 5.1 Particle Size Distribution of 
Freeze-Dried Propranolol/Alginate Complex 
Suspended in Deionised Water 
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5.3.2 Propranolol Content 
5.3.2.1 Materials and Equipment 
Propranolol/alginate complex (section 5.2 above); 
Sodium chloride BN 6794910K (BDH, Poole, Dorset); 
AnaLar water BN 3137510L (BDH, Poole, Dorset); 
Uvikon 860 UV Spectrophotometer, Kontron Instruments, England. 
All reagents were used as received. 
5.3.2.2 Methods 
In order to determine the propranolol content of the 
complex, a calibration curve for propranolol was constructed (Figure 
5.3). Three different known weights of the complex (20mg, 33mg 
and 40mg) were then dissolved in 1000mL of 0.9% sodium 
chloride solution and analysed in the UV spectrophotometer at 
288nm for propranolol concentration. Each determination was 
performed in triplicate. 
5.3.2.3 Results 
The results from the determination of propranolol content 
are shown in Table 5. 1. 
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Figure 5.3 Calibration Curve for UV 
Spectrophotometric Determination 
of Propranolol at 288nm 
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Table 5.1 Oetennination of the Propranolol Content of the 
P r o p r a n o l o l / A l ~ i n a t e e Complex 
Weight of UV Abs. 
preCipitate at 288nm 
dissolved in {n=3, 
1000mL 50<0.005) 
19l 
0.020 0.259 
0.033 0.428 
0.040 0.516 
Concentration 
of propranolol 
(from calibration 
curve) 
~ - 1 1 1
0.0131 
0.0218 
0.0263 
Proportion of 
;gropranolQI in 
p r e c i p i t a t ~ ~ . 
(%w/w) 
65.5 
66.1 
65.8 
Mean = 
65.8%w/w 
The mean percentage of propranolol in the preCipitate was 
measured as 65.8%w/w. This is slightly higher than the theoretical 
calculation of propranolol content based on molecular weights, 
assuming that one molecule of propranolol is bound to one carboxyl 
group on each hexose unit on the alginate. In this case, the 
theoretical proportion of propranolol in the complex would be 
calculated as 60%w /w as follows: 
MW propranolol = 296; 
MW of one guluronic or mannuronic acid residue = 200: 
Therefore. assuming one-to-one binding. the percentage of 
propranolol within the complex would be: 
296/(296 + 200) x 100 = 60%w/w. 
However. it is probable that, despite repeated washing of the 
preCipitate duIing its preparation to remove free propranolol. sonle 
free propranolol remained which was freeze-dIied with the 
propranolol/ alginate complex. 
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5.3.3 IN VITRO DRUG RELEASE STUDIES FROM THE 
PROPRANOLOL/ALGINATE COMPLEX 
5.3.3.1 Introduction 
In vitro experiments were set up to investigate the rate of 
release of propranolol from the propranolol/alginate complex across 
a semi-permeable membrane. The system employed was dialysis 
across a semi-permeable Visking membrane (of the same type used 
for the equilibrium dialysis experiments in Chapter 4) into 0.9% 
sodium chlOride solution. 
5 . 3 . 3 . 2 ~ t e r i a l s s
Propranolol/alginate complex formed in section 5.2 above: 
AnaLar water BN 3137510L (BDH, Poole, Dorset); 
Sodium chloride (BDH, Poole, Dorset); 
Visking dialysis tubing (cut-off point 5,000 Daltons). 
5.3.3.3 Methods 
The following formulations were tested: 
(t) Propranolol solution IgL-l; 
(il) Propranolol solution 5gL-l; 
(ili) Propranolol solution 1 OgL -1 ; 
(tv) Alginate/propranolol complex formulated as a suspension in 
deionised water (equivalent to 109 of propranolol in 1 L of 
suspension) ; 
(v) Alginate/propranolol complex formulated as a suspension in 
isotoniC glycerol solution (equivalent to log of propranolol in 1 L of 
suspension) . 
For each of the above formulations, 5nlL of solution/ 
suspension was placed in a dialysis bag (1 OOmm long x 50mm 
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diameter of the same Visking tubing used for the equilibrium 
dialysis experiments described in Chapter 4). This was immediate Iv 
placed in a flask containing 500mL of 0.90/bw /v sodium chlOride 
solution, previously heated to 370 C and placed in a shaking water 
bath at 37oC. 
3mL samples were withdrawn from the flask at intervals up to 
150 minutes and analysed for propranolol concentration at 
wavelength 288nm. 3mL of 0.9%w /v sodium chloride solution was 
added to the flask after each sampling in order to keep the volume 
of fluid constant. Each experiment was performed in triplicate. 
Standard deviations were less than 0.5% in all cases. 
5.3.3.4 Results 
Figure 5.4 shows plots of percentage of drug released versus 
time for the solutions containing 19L-1, 5gL-1 and 10gL-l of 
propranolol. Since the percentage release of propranolol over time 
was similar for all these solutions and appeared to be dependent 
only on the rate of diffusion of the drug across the membrane. it was 
decided to compare only the 10gL-l solution with suspensions of 
the propranolol/alginate complex containing an equivalent amount 
of propranolol. 
Figure 5.5 shows the in vitro release profile for the 
propranolol/alginate complex 15.2gL-1 in deionised water 
(equivalent to 109 propranolol in 1L of suspension) compared with 
that for propranolol solution 10gL-1. Figure 5.6 shows the in vitro 
release profile for the propranolol/alginate complex 15.2gL-1 in 
isotonic glycerol solution (equivalent to 109 propranolol in 1 L of 
suspension), compared to the profile for propranolol solution 
10gL-1. 
Figure 5.7 is a comparison of the release profile of 
propranolol from the complex formulated in AnaLar deionised water 
and in isotonic glycerol solution. 
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Figure 5.7 Comparison of Release Profile 
for Propranolol/Alginate Complex in 
Deionised Water and in Isotonic Glycerol 
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5.4 DISCUSSION 
From Figures 5.5 and 5.6 it can be seen that there is a lag of 
approximately 5-6 minutes in the release proille for the 
propranolol/ alginate complex compared with the propranolol 
solution. The profile for the solution would be expected to be 
dependent only on the rate of diffusion of propranolol through the 
semi-permeable dialysis membrane, but for the propranolol/alginate 
complex, several processes may be occurring. Na+ ions diffuse into 
the dialysis bag and since the affinity of the sodium ions for alginate 
is greater than that of the propranolol ions (Chapters 3 and 4). ion 
exchange occurs releasing drug and dissolving the propranolol/ 
alginate complex. The propranolol ions can then diffuse out of the 
dialysis bag into the sodium chloride solution. The lag time of 5-6 
minutes observed suggests that this time is taken whilst the 
preCipitate is ion-exchanging and dissolving. as subsequently the 
profile is almost identical to that of the solution. 
Therefore. it would appear that when propranolol is 
formulated as a complex with alginate in suspension. there is some 
evidence for delayed release relative to that of a propranolol 
solution. Furthermore, from Figure 5.7 it can be seen that the 
presence of glycerol as an agent to adjust tonicity did not appear to 
affect the release of propranolol from the complex compared to the 
release of propranolol from the complex formulated in deionised 
water. 
5.5 CONCLUSIONS 
A freeze-dried propranolol/alginate complex has been 
prepared from propranolol hydrochloride and the sodium alginate 
Laminaria hyperborea. 
When tested in vitro for release of propranolol across a 
semi-permeable membrane, it was found that release of propranolol 
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from the complex (formulated as a suspension in either AnaLar 
deionised water or in isotonic glycerol) was slightly delayed 
compared with release from a propranolol solution. 
The release of propranolol from the formulations was then 
assessed in vivo using the anaesthetised rat as an animal model for 
nasal delivery. This is described in the following chapter. 
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CHAPTER 6 
IN VIVO DRUG ABSORPTION STUDIES 
6.1. INTRODUCTION 
Nasal delivery in the rat was chosen as a model in vivo system 
in which to investigate the potential of alginate ionic complexes to 
control drug absorption. Propranolol is a relatively small (MW 295). 
lipophilic drug (log P octanol/water = 3.36) with a pKa of 9.45. It is 
rapidly absorbed Intranasally in rats and Its systemic bioavailability by 
this route is nearly 100% relative_to an intravenous dose (Hussain et 
al 1980b). 
6.1.1 Nasal delivery - background 
As a site for the absorption of various compounds. the nasal 
cavity is not a recent discovery. For example. the South American 
Indians and certain African Witchdoctors are reported to have used 
snuffs made from mediCinal plants in the treatment of disease. and 
the use of tobacco snuff in England dates back to the seventeenth 
century. when it was introduced by Sir Walter Raleigh (Bowman and 
Rand 1980). More recently the abuse of cocaine and Similar drugs by 
'snorting' has become more widespread. 
It was not until the twentieth century that the first cases of 
compounds being systemically absorbed after intranasal (IN) 
administration were reported in sCientific literature . For example. 
in 1922. Blumgart demonstrated the antidiuretic effect of intranasal 
pituitary extract employed in the treatment of diabetes inSipidus. 
and Cohen et al (1930) reported the absorption of ragweed pollen 
introduced into the nasal cavity. In 1932. several workers delivered 
insulin intranasally to human diabetics. by combining it with 
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saponin, although this resulted in symptoms of congestion and 
rhinitis. 
Over the last decade, the number of publications concerning 
nasal absorption has increased rapidly. Two comprehensive reviews 
of substances applied to the nose for both topical and systemic 
effects have been published (Chien 1985: Chien and Chang 1987). 
These authors have outlined the vast range of compounds which 
have been administered via the nose with varying degrees of 
success, for example, cardiovascular drugs, antimicrobial biologicals, 
CNS stimulants and numerous honnones. to name but a few. Despite 
all the scientific publications, there still remains only a scant 
number of drugs which are administered nasally for their systemic 
effects. These include vasopressin (anti-diuretic honnone) and 
desmopressin which are both used in the treatment of pituitary 
diabetes inSipidus, and oxytOCin which is used to induce labour in 
pregnant women. 
Traditionally, the intranasal route has been associated with 
the topical treatment of local conditions, for example allergic 
rhinitis, although it has been shown to be suitable for certain drugs 
intended to have a systemic effect, but which demonstrate poor oral 
bioavailability. Therefore, as an alternative to the injection of drugs. 
the nasal route is becoming increasingly popular. This is because, in 
common with other parenteral routes, drugs crossing the nasal 
mucosa pass directly into the systemiC circulation (Parr 1983). For 
many drugs, the rate and extent of IN absorption, closely resemble 
that of an intravenous (IV) dose, but for the patient, the nasal route 
offers a better alternative to repeated injection. In addition, the nose 
is easily accessible for drugs to be administered in the fonn of 
drops, sprays or gels, and as a surface for absorption the nasal cavity 
is well supplied with blood and has numerous cells with microvilli or 
cilia. Compared with the gastrointestinal tract, there is a much more 
favourable environment, since breakdown of drug in the gut lumen 
or wall, and first-pass metabolism by the liver are avoided. 
The systemic bioavailability and therefore the efficacy of drugs 
is often influenced by the route of administration selected. For a 
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drug to be at its maximum therapeutic efficiency, it should be 
absorbed rapidly, and administered easily, so that. for many drugs. 
the nasal route of administration would seem to be an excellent 
choice. However, a variety of both biological, physico-chemical and 
pharmaceutical factors can affect the absorption of drugs via the 
nose into the systemic Circulation. These are discussed below for 
nasal delivery of drugs to humans. 
6.1.2 Factors aflectiJli nasal delivery. 
6.1.2.1 Structure and function of the nasal cavity 
Various texts are available which provide detailed 
descriptions of the anatomy of the nasal cavity in man (Mygind 
1985; Chien and Chang 1987) and in animals (Popp and Martin 
1986; Keleman 1947), and the reader is referred to these for more 
detailed accounts. In summary, the nasal cavity is divided by a 
midline septum composed of bone and cartilage, with each half 
being separated into three regions: the vestibule (the region just 
inside the nose); the olfactory region (covering the roof of the nasal 
cavity, and some of the upper portions of the nasal septum and 
lateral walls) and the respiratory region (the rest of the cavity). The 
absorptive surface is the nasal mucosa, which is composed mainly of 
epithelial cells. The 'mucociliary apparatus' which is comprised of 
ciliated epithelial cells and glandular tissue, secretes a layer of 
mucus onto the surface of the epithelium, which prevents it drying 
out and, together with coarse hairs in the vestibular region, also 
forms a defence system for removing inhaled pollutants. 
The main function of the nasal cavity is a protective one, 
whereby inhaled air is filtered, warmed and humidified in 
preparation for gaseous exchange in the lungs (Mygind 1985). Hairs 
and mucus within the cavity trap particles, which are then renloved 
either mechanically or by the action of the mucociliary apparatus. 
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The olfactory function of the nose also acts as a protective 
mechanism by aiding in the detection of possible poisonous gases 
(Negus 1958). 
It can be seen that the structure of the nasal cavity can 
represent a barrier to the absorption of drugs, since the drug must 
pass through both the surface mucus layer and the mucous 
membrane itself, whilst avoiding mucociliary clearance, before it 
reaches the systemic circulation. 
6.1.2.2. Metabolism within the nasal cavity 
Although the total metabolic capacity of the nasal cavity has 
yet to be defined, a number of enzyme systems have been identified 
which are thought to have an important function in metabolically 
inactivating and/or detoxifying foreign substances. Therefore it is 
possible that various metabolic processes may interfere with the 
absorption of drugs administered via the nose and may also produce 
inactive or toxic metabolites. 
6.1.2.3. Bioloelcal factors 
Respiratory infection such as the common cold usually result 
in the production of either a watery mucus which could cause 
'washing out' of the dose, or a thick viscous mucus which could 
prevent the dose reaching the absorptive surface. In addition, 
mechanical clearing of the nasal cavity, for example by sneezing or 
blowing the nose, is a potential source of drug loss. 
Certain conditions such as allergic rhinitis have been shown 
to increase absorption of drugs by an increase in the 'leakiness' of 
intracellular junctions (Inagaki et al 1985), whilst the presence of 
polyps or tumours would reduce the volume of the nasal cavity and 
could interfere with distribution of the dose within the nose. 
The blood supply to the nose can be affected by both 
emotional factors such as stress, and environmental factors, such as 
-147-
temperature. Exposure to adverse conditions, for example Cigarette 
smoking, over prolonged periods can also result in damage to the 
nasal mucosa (Proctor 1977). 
6.1.2.4. Physico-chemical factors 
The passage of a drug from the nasal cavity into the systemic 
Circulation reqUires it to move from the aqueous boundary layer 
covering the surface of the nasal mucosa across the lipid banier 
membrane, and then to diffuse across the cell and on into the 
circulation. For this reason, the physicochemical properties of the 
drug such as its pKa, lipophilicity and molecular size will influence 
the extent and rate of absorption. 
In general, unionised molecules are more readily absorbed 
across mucosal membranes, so that changes in the pH of either 
nasal secretions or of the drug solution could affect absorption. The 
pH of the nasal cavity has been reported to be around 5.5-6.2 in 
humans and between 7.2-7.4 in the rat (Hirai et al 1981). The 
absorption of lipophilic drugs will be limited by the rate of diffusion 
across the aqueous boundary layer, whilst for hydrophilic drugs, 
partitioning into the lipid membrane will be the rate-limiting step. 
Although it has been demonstrated that drugs with a wide range of 
molecular weights have crossed the nasal mucosa, it is generally 
found that drugs with a molecular weight of greater than 1000 are 
less well absorbed (McMartin et al 1987). 
6.1.2.5. Phannaceutical factors 
The dosage from used to administer a drug to the nose could 
affect the eventual absorption of the drug form the nasal cavity. For 
example, it would seem likely that drug molecules would reach the 
absorptive surface more quickly from aqueous solutions than when 
having to diffuse through a viscous gel network. 
In humans, it is usual to administer nasally-delivered drugs in 
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an isotonic formulation in order to minimise irritation to the nasal 
mucosa. However, some workers have demonstrated that absorption 
of drugs can be modified by using non-isotOnic formulations 
(Daugherty et al 1988). 
Finally, the use of excipients (such as surfactants, bile salts. 
chelating agents, fatty acids or enzyme inhibitors) to enhance nasal 
absorption is well documented (for example, Lee et al 1991), 
although certain excipients may be added, for example, to increase 
the stability or tonicity of a formulation. Therefore, it should be 
appreciated that added excipients have the potential to affect the 
absorption of a drug from the nasal cavity. 
6.1.3 Nasal delivery of propranolol 
Propranolol hydrochloride is usually given as an oral dose, but 
may also be administered intravenously for the treatment of 
arrhythmias. 
Shand et al (1970) reported that oral administration of 
propranolol to five human subjects resulted in great variability in the 
plasma levels measured. Peak plasma levels after an 80mg oral dose 
varied as much as sevenfold, compared to only a twofold variation in 
the same subjects after IV administration of a 10mg dose. In the 
same study it was estimated that the systemiC bioavailability of an 
oral dose of propranolol ranged from 16% to 60% of the 
bioavailability of the IV dose. The authors suggest that these 
differences could be the result of extensive frrst-pass metabolism of 
propranolol by the liver after an oral dose. 
Intranasal (IN) administration of propranolol was investigated 
as a method of enhancing drug bioavaHability and minimising the 
variation in blood levels seen with other non-parenteral routes 
(Hussain et al 1979). Propranolol was administered to the nasal 
cavity of Sprague-Dawley rats with a micropipette. The results 
indicated that the blood drug levels for IV and IN administration of 
1mg doses were identical. whereas oral administration resulted in 
considerably lower blood levels. The authors concluded that: 
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(a) Propranolol is rapidly absorbed from the nasal mucosa 
with peak plasma levels being obtained within five minutes of 
ins tillation; 
(b) The nasal route for administration of propranolol appears 
to be as effective as the IV route and superior to the oral route. 
In another study by the same workers, the benefits of nasal 
administration of propranolol were demonstrated further in rats and 
dogs (Hussain et al 1980a). A sustained-release formulation of the 
drug incorporated with methylcellulose was administered 
intranasally. The investigations suggested that the sustained-release 
preparation resulted in low initial but prolonged blood levels. such 
that the bioavailability was identical to that of the IV route. 
Hussain et al (1980b) also evaluated the nasal absorption of 
propranolol in human subJects, and compared it with IV and oral 
administration. Their results demonstrated that IN administration of 
propranolol hydrochloride in 2% methylcellulose gel produced a 
blood level identical to that obtained after IV infusion. However, the 
oral bioavailability from propranolol tablets was found to be only 
250k. These findings were in agreement with the previous studies in 
rats and dogs. 
6.1.4 Use of an anaesthetised rat model for intranasal studies 
The use of animal models to study the absorption of drugs 
across the nasal mucosa is well known (Gizurarson 1990). with the 
rat and the dog being the two most commonly used species. For 
certain nasally administered drugs, animal models allow prediction 
of in vivo profiles in man. For example, Hussain et al (1979. 1980a 
and 1980b) demonstrated a good correlation between the nasal 
absorption of propranolol in rats, dogs and man. However, it should 
be noted that for other drugs, for example insulin, significant 
differences in absorption between species have been documented 
(Verhoef et al 1989). 
In the work described in this chapter, an in vivo 
anaesthetised rat model modified from that described by Hirai et a1 
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(1981) was used. Possible disadvantages of this model are that 
various factors including anaesthesia, surgical intervention and 
orientation of the animal may result in changes in the absorption of 
drugs through the nasal mucosa. For example, Daugherty et al 
(1988) reported that absorption of methionyl recombinant human 
growth hormone was greater from an in vivo anaesthetised rat 
model than from the conscious animals. 
6.2 MATERIALS 
Sodium hydrOxide BN 21694101 (Fisons, Loughborough. Leics.); 
Heptane BN 2377520L (BDH, Poole, Dorset); 
Iso-amyl alcohol BN 4040032 (Sigma Chemical Co., St. Louis. U.S.A.); 
Hydrochloric acid (BDH, Poole, Dorset): 
Propranolol hydrochloride BN 8905237 (CP Pharmaceuticals. 
Loughborough, Leics.); 
Bench Centrifuge Centaur 2 (MSE, Loughborough. Leics.); 
Perkin -Elmer 3000 Fluorescence spectrometer (Perkin-Elmer. 
Beaconsfield, Bucks.); 
AnaLar deionised water BN 3137510L (BDH, Poole, Dorset). 
All materials were used as received. 
6.3 METHODS 
6.3.1 Study desten 
The study was designed to compare the intranasal absorption 
of propranolol from a solution with its absorption from a complex 
with alginate. Many routes of drug administration. for example 
injections, require formulations which are isotoniC with blood 
serum, in order to avoid haemolysis (if the solution is hypotonic) or 
damage to vein walls (if the solution is hypertonic). Nose drops are 
usually formulated to be isotoniC with natural nasal secretions. Whilst 
this is not essential, it reduces the transient stinging and soreness 
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associated with administration of non-isotOnic solutions to humans. 
It was therefore deCided to prepare an isotonic fonnulation of the 
propranolol/ alginate complex using glycerol solution, in order to 
investigate if an osmotic effect would influence drug absorption from 
the complex. Glycerol was chosen since it is non-ionic and it had 
previously been demonstrated (section 3.2.5) that ionic salts such as 
sodium chloride (which are often used to adjust tonicity) caused the 
propranolol/alginate complex to dissociate. The concentration of 
glycerol solution used was 26gL-l (that is, the concentration stated 
as being iso-osmotic with blood by the Phannaceutical Handbook 
Nineteenth Edition (1980)). 
6.3.2 Preparation of Doslni Solutions/Suspensions 
The alginate/propranolol complex was prepared as described 
in section 5.2. Three different fonnulations were administered: 
(1) Dose group 1: propranolol solution in deionised water; 
(il) Dose group 2 : propranolol suspension (containing propranolol/ 
alginate complex in deionised water; 
(iii) Dose group 3 : propranolol suspension (containing propranolol/ 
alginate complex in isotonic glycerol solution). 
6.3.3 Animal Model - Suretcal Procedures 
Anaesthetised male Sprague-Dawley rats (body weight 250g to 
330g) were used in all experiments. The rats were starved for 12 
hours prior to dosing. AnaestheSia was induced by intraperitoneal 
administration of urethane (1.25g/kg of either a 100A)w/v or 40% w/v 
solution), and maintained by additional doses of ImL of a 400/ow/v 
solution as required. 
In summary, the surgery perfonned on the animals 
comprised: a tracheotomy to maintain respiratory function during 
anaestheSia: isolation and ligation of the oesophagus to prevent 
drainage of any intranasally administered drug into the gut: and 
cannulation of the Jugular vein for collection of blood samples. 
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Each anaesthetised rat was laid ventral side uppermost and 
an incision was made in the skin over the trachea exposing the 
underlying muscle. The muscle layer over the trachea was carefully 
dissected and a transverse incision made in the upper surface of the 
trachea. A cannula (3.0mm o.d.; 2.0mm Ld.) was inserted through 
the incision and into the trachea. This cannula was secured with 
thread. The oesophagus was isolated and ligated using thread. 
Using blunt dissection. the jugular vein on one side of the 
neck was exposed and ligated distal to the heart. An incision was 
made in the vein. midway along the exposed section, between the 
ligature and the heart. and a cannula (l.Omm o.d.: 0.5mm Ld.) was 
inserted and secured using a ligature. The cannula was kept free 
from clots by flushing with a saline solution containing heparin 
(25 U mL -1). Mter removing each blood sample the cannula was 
flushed through with a small volume of heparinised saline. 
6.3.4 DnJf Administration 
Mter the surgery described in section 6.3.2 had been 
performed. each animal was laid ventral side uppermost on a heated 
work surface to prevent hypothermia during anaesthesia. A IOOf..l1 
Hamilton syringe was filled via a length of polypropylene tubing 
(O.Bmm o.d.; 0.4mm Ld.) attached to the needle. with 50f..l1 of the 
dose solution/ suspension. The tubing was inserted apprOximately 
2mm into the rat nostril. and the dose administered as a bolus ( ~ ~ 30 
seconds to dose). At time zero, each rat received equivalent to Img 
of propranolol in solution/ suspension in a 50f..l1 volume. delivered as 
a single dose into one nostril. 
6.3.5 Sample Collection 
Blood samples (1 OOIll) were withdrawn from the Jugular veln 
cannula and collected into heparin1sed tubes at 2. 5. 10, 15. 30. 45. 
60. 90. 120. 150, 1BO. 210 and 240 minutes after admlnistration. 
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Plasma was collected by centrifuging samples at 300 r.p.m. for 2 
minutes. 
For dose group 3, blood samples were only collected until 
120 minutes after drug administration. This was because the rats in 
this group had not been starved prior to administration of urethane. 
and the resultant increase in absorption of the anaesthetic proved 
fatal to the rats after 120 minutes. 
6.3.6 Spectrofluorimetric Assay for Plasma Propranolol 
Plasma concentrations of propranolol were detennined by a 
spectrofluorimetrtc assay developed by Critchley (1989). This was 
modified from a technique deSCribed by Shand et al (1970) who 
reported that the assay is free from interference by metabolites of 
propranolol. 
Fluorescence measurements were made on a Perkin-Elmer 
3000 Fluorescence Spectrometer using a 1 cm path length quartz 
cell. The maximum excitation and emission wavelengths of 
propranolol in O.lM HCI were found to be 28Snm. and 34Snm. 
respectively. A slit width of Snm. was used for both the excitation 
and emission wavelengths. Measurements were taken as the mean of 
five successive readings. 
To remove contaminants which could result in background 
fluorescence. all glassware was surface cleaned with chromiC acid 
and rinsed five times in tap water and five times in distilled water 
prior to use. 
6.3.7 Standard Curve 
In order to allow a quantitative determination of propranolol 
concentration in unknown samples, a standard curve of fluorescence 
vs. propranolol concentration was detennlned on the day of each 
assay. Standard solutions of propranolol in O.lM HCI (2.S. S. 10. 20. 
40,50 and 100 ng mL-1) were prepared by dilution ofa O.lmg mL-l 
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stock solution. The fluorescence of each standard was measured in 
triplicate, and a standard cUlVe of fluorescence vs. propranolol 
concentration was constructed. This was found to be linear over a 
range of concentrations. A typical standard cUlVe is illustrated in 
Figure 6.1. 
6.3.8 Extraction of Orne from Plasma 
All the plasma samples were extracted prior to spectro-
fluorimetric assay. After storage in a freezer at -20oC they were 
thawed at room temperature. 2 5 0 ~ 1 1 of distilled water was added to 
5 0 ~ 1 1 of plasma in a glass test tube and make alkaline by the addition 
of 2 5 0 ~ 1 1 of 1M NaOH. This mixture was extracted into 3mL of 
iso-amyl alcohol (1.50/0) in heptane. by vortexing for three minutes 
and centrifuging for 10 minutes at 3000 r.p.m. (The iso-amyl alcohol 
in heptane was added as 5 0 ~ L L iso-amyl alcohol and 2.95mL heptane 
due to variable extraction efficiencies when a stock mixture was 
used). 2mL of the heptane layer was removed and placed in a clean 
test tube. 3mL of O.lM hydrochloric acid was added and the mixture 
vortexed for 3 minutes. then centrifuged as before (3000 r. p.m. for 
10 minutes). The upper organic phase was removed and the acid 
layer assayed spectrofluorimetrically for propranolol using 0.1M HCI 
as the blank. 
6.3.9 Efficiency/Reproducibility of the Extraction Procedure 
Blank rat plasma ( 1 0 0 ~ 1 ) ) was spiked with a known amount of 
propranolol. then extracted and assayed as outlined above. The 
typical extraction efficiency was found to be 90 ± 1.2%. therefore 
this correction factor was applied to all future samples assayed. 
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6.4 PHARMACOKINETIC PARAMETERS 
6.4.1 Area Under The Curve (AU e) 
The area under the plasma time curve (AUe) following IV or 
IN administration reflects the amount of drug absorbed systemically 
and can be determined by numerical integration from t=o to t=oo. 
The AUe was calculated for each of the three dosage fonns 
above using a computer program written by Dr. P. J. Kirk 
(Department of Physics, University of Nottingham). This program 
calculates a minimum value taking the last point of the curve (that 
is, time = 240 minutes for Figure 6.2) as the cut-off point, and a 
theoretical maximum value (curve extrapolated to zero 
concentration using a least-squared fit procedure on the last five 
data points) for area under the curve. It was tested using 
measurements from Hussain et al (1980b) and was found to generate 
results in agreement with these workers. The program is listed in 
Appendix 2. 
6.4.2 Absolute BloavaJJabUity (F%) 
Bioavailability may be defined as the rate and extent to which 
drug is absorbed and becomes available to the systemic circulation 
(Wagner 1975). Therefore, it is a useful parameter for comparing 
drug absorption from different formulations administered via the 
same route. 
IV administration is considered to result in complete 
bioavailability since drug is introduced directly into the systemic 
circulation. Thus, absolute bioavailability (FVo) may be calculated by 
comparing Aue data obtained follOwing IV dosing with AUe data 
from extravascular dosing: 
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FVo = 
where: 
AUCo_ 00 e.v. Dose Lv. 
x x 100 
AUCo_ 00 Lv. Dose e.v. 
AUC = area under the plasma time curve; 
Dose Lv. = intravenous dose; 
Dose e.v. = extravascular dose. 
6.4.3 Relative BioavallabWty CFo/OreIl 
(Equation 6. 1) 
The determination of absolute bioavatlability requires both IV 
and extravascular administration of a drug. However, relative 
bioavailability (FOlOrel) can be employed to compare different 
formulations of the same drug administered extravascularly. and may 
be calculated using equation 6.2: 
FllOrel = AUCo- 00 e.v.(l) Dose e.v.(2) 
x x 100 (Equation 6.2) 
AUCo_ 00 e.v.(2) Dose e.v.(l) 
6.5 RESULTS 
Mean plasma concentration versus time profiles for the 
formulations of propranolol outlined in section 6.3.1 are shown in 
Figure 6.2. 
It can be seen from the results for Dose Group 1 (propranolol 
solution) that the absorption of propranolol from the nasal cavity of 
rats was rapid, resulting in a sharp peak in plasma levels 5 minutes 
after administration, followed by a rapid decline in the plasma 
concentration/time curve. 
Administration of propranolol as an alginate complex (Dose 
Group 2) resulted in a significant change in the rate of drug 
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absorption compared to the solution fonnulation. For the complex. 
the absorption rate was much slower With peak plasma levels being 
achieved after 60 minutes, but was sustained over a greater period of 
time. 
The presence of glycerol to adjust tOniCity (Dose Group 3) did 
not appear to markedly change the absorption profile for the 
propranolol/ alginate complex in rats, in comparison with Dose 
Group 2. 
6.5.1 Area Under the Curve (AUC) 
The areas under the curves for each of the dosage fonns were 
calculated using the computer program in Appendix 2 as follows: 
(1) Dosage Form 1 (Propranolol solution): 
AUe: Minimum = 990: 
Maximum = 1047 ± 2. 
(ii) Dosage Form 2 (Alginate/propranolol complex in deionised 
water): 
AUe: Minimum = 987: 
Maximum = 1113 + 10. 
(iii) Dosage Form 3 (Alginate/propranolol complex in isotonic 
glycerol solution): 
The area under this curve could not be compared to the 
values for (1) and (ti) above, as data was only available up to two hours 
into the experiment (section 6.3.4), compared to four hours for the 
above. However, it can be seen from Figure 6.2 that curve (iii) 
followed a very similar pattern to curve (ti). with peak plasma levels 
occurring at 60 minutes after administration, therefore provided 
that this trend continued. which seems likely, it can be assunled 
that. in rats, the presence of glycerol does not affect the rate of 
absorption of propranolol from the propranolol/alginate cOInplex. 
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Table 6.1 lists the pharmacokinetic parameters Aue and 
Relative Bioavailability described above, calculated for Dose Groups 1 
and 2 using equation 6.2. 
Table 6.1 Pharmacokinetic Parameters after Nasal 
Administration of Propranolol to Rats 
Formulation 
Solution 
(Dose Group 1) 
Sustained release 
(Dose Group 2) 
AUCo-oo 
(nil hr) mL-1 
1047 ± 2 
1113±10 
Dose 
~ ~
1 
1.1 
Relative 
Bioavailability 
(%) 
100 
97 
The results for Dose Group 1 (propranolol solution) 
correspond well with previously published results for nasal 
absorption of propranolol in rats (Hussain et al 1980b). These 
workers reported a nasal bioavailability of 99.9% compared to that of 
an IV dose. 
6.5.2 Relative BioavatJabllity 
A comparison of the results for relative bioavailability from 
Table 6. 1 indicates that there is little difference in the bioavailability 
of propranolol delivered nasally to rats as a solution (Dose Group 1) 
or as a complex with alginate (Dose Group 2). 
6.5.3 Absolute BioavatJabllity 
Hussain et al (1980b) have published bioavailability data 
following IV administration of propranolol to rats. Their 
experiments were perfonned using the same dose of propranolol in 
rats of a similar size to those employed in these investigations. 
thereby allowing a comparison with the bioavailabilities for 
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Dose Groups 1 and 2 to be made with reasonable confidence. The 
AUC calculated by Hussain et al (1980) for IV administration of 
propranolol was 1033.8 ± 30.8 ng hr mL-l. 
The results for Dose Group 1 (absolute bioavailability = 101 ± 
3%, calculated using equation 6.1) are in agreement with Hussain et 
al (l980b), who reported an absolute bioavailability of 1000/0 for 
propranolol solution delivered IN, compared to an IV fonnulation. In 
comparison with the IV results published by Hussain et ale for the 
formulation containing the propranolol/alginate complex. the 
absolute bioavailability is 98 ± 30/0. 
6.6 DISCUSSION 
From the results above it can be seen that. by complexing 
propranolol with alginate, it is possible to control the rapid release 
of propranolol usually observed after nasal delivery of the drug in 
solution, whilst still retaining a systemic bioavailability comparable 
to that of the solution. The use of a sustained release fonnulation 
based on alginate complexation may have important advantages for 
drugs such as propranolol which are rapidly absorbed via the nasal 
route. For example, the results in rats indicate that it may be 
possible to eliminate the 'peaks and troughs' in plasma drug 
concentration which are often observed with conventional dosage 
forms. In humans, this may markedly reduce the incidence of 
unwanted systemiC or local side-effects and could thereby iInprove 
patient compliance. 
It is postulated that the mechanism of release of propranolol 
from the complex in the nasal cavity may follow the pattern 
demonstrated in vitro in Chapter 5. The alginate and propranolol are 
administered intranasally as an ionic complex suspended in 
deionised water. Cations, including sodium and calciuln. which are 
present in the rat nasal fluids (Chien and Chang 1987) cause the 
propranolol/alginate complex to dissociate as the propranolol on the 
alginate is slowly ion-exchanged by these cations. The in vitro 
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experiments (Chapter 5) did not suggest that propranolol release 
from the complex would be sustained for the relatively long period 
of time observed in the in vivo experiments. From the in vitro 
experiments. it was thought that once the insoluble complex had 
dissolved by formation of soluble sodium alginate. absorption of 
propranolol in vivo would follow the rapid pattern nonnally observed 
with administration of propranolol solution. However. the sustained 
release observed in vivo may be due to other factors. For example. 
whilst ions such as calCium may displace propranolol from the 
propranolol/ alginate complex. they may also cause the alginate to 
gel. thereby delaying the absorption of free propranolol. since it 
would have to diffuse through the gel network before being absorbed 
through the rat nasal mucosa. Mucus in the nasal cavity may also act 
as a barrier to the absorption of propranolol, compared to the 
results observed in vitro when no mucus was present. 
The mechanism by which drugs are absorbed across the nasal 
mucosa is not yet fully understood. The pH of the nasal cavity has 
been quoted as 7.2-7.4 (Hirai et al1981). which would suggest that 
the ionised form of propranolol would predominate (pKa 
propranolol = 9.45). However. there must be sufficient of the 
unionised form present to allow good absorption to take place, since 
the absorption of propranolol has been found to be both rapid and 
dose-dependent (Critchley 1989). In addition, propranolol is a 
relatively small and lipophilic drug (MW 295: log P octanol/water 
3.36). thus Hirai et al (1981) indicate that the most likely 
mechanism for its absorption is by transcellular diffusion in 
accordance with the pH/partition hypothesis. 
The anaesthetised rat is useful for preliminary investigations 
of the absorption characteristics of nasally delivered propranolol. 
However. as discussed in section 6.1.4. it cannot be totally 
representative of the physiological situation in man, since there may 
be differences in absorption due to anaesthesia, surgical intervention 
or orientation of the rat. For example, the animals were 
anaesthetised with urethane. Propranolol is knO\VIl to be 
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predominantly eliminated from the body by the liver and the lung 
(Frishman 1979). Thus. the pharmacological effects of the 
anaesthetic which include lowering of basal metabolic rate and 
changes in hepatic function may result in a difference in nasal 
absorption between conscious and anaesthetised animals. Also. 
during surgery. the oesophagus was tied off to prevent drainage of 
intranasally administered propranolol into the gut. This would not 
be representative of the case in a conscious human subject. where 
propranolol could drain freely into the gastrointestinal tract. Finally. 
in these studies. the animals were dosed while lying horizon tally on 
their backs. This could lead to dose pooling over the upper regions 
of the nasal cavity. and cannot therefore be directly compared to the 
situation when a man is dosed in an upright vertical position. 
Despite the favourable results reported in these experiments 
and by Hussain et al (1980b). there is a drawback to the nasal 
administration of propranolol. The nasal ciliary epithelium plays an 
important role in the removal of dust. allergens and micro-
organisms which may be deposited in the nose during inhalation. 
Van de Donk and Merkus (1982) investigated the chroniC effect of 
long-term IN administration of propranolol on the ciliary beat 
frequency in chicken embryo and human adenoid tissue. Their 
results demonstrated that propranolol in nose drops arrested the 
movement of chicken and human cilia within twenty minutes of 
administration of doses of 10/0 and O.loAl respectively. Another study 
reported a significant reduction in mucociliary clearance after oral 
administration of propranolol to humans. This toxiC effect of 
propranolol has also been found with other cilia-like structures. for 
example the flagella of human spennatozoae (Zipper et al 1983). For 
these reasons. propranolol is unacceptable for long-tenn therapy if 
delivered intranasally. 
However. in these experiments propranolol was employed 
only as a model cationiC lipophiliC drug. The results have 
demonstrated that the complexation of this cationiC drug \\'ith an 
alginate results in more sustained release rates fronl the complex 
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than from a drug solution alone. That is, it may be possible to slow 
down and sustain the release of drugs which are rapidly absorbed 
through the nose, without affecting the bioavailability of these drugs. 
This may prove to have important consequences for a variety of 
other substances which could be delivered intranasally. 
6.7 CONCLUSIONS 
The nasal delivery to rats of a propranolol/ alginate complex 
resulted in a significant reduction in the rate of drug absorption 
compared to a solution formulation. The rate of absorption of 
propranolol from the complex was much slower and was sustained 
over a greater period of time, compared with absorption from 
solution. 
The systemic bioavailability of the drug from the complex was 
comparable to that of the solution, and to that of an IV dose carried 
out in rats by other workers (Hussain et al 1980b). 
It is possible that the results reported above for the model 
drug propranolol and the polysaccharide sodium alginate may be 
applicable to other drug/polysaccharide systems, which could be 
used in the future to develop sustained release delivery systems for 
use in humans. It would therefore be of benefit to continue these 
investigations using other combinations of drugs and 
polysaccharides. 
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CHAPTER 7 SUMMARY 
The aim of the work in this thesis was to achieve a greater 
understanding of the fundamental mechanisms and factors 
controlling the interaction of an anionic polysacchartde polymer. 
sodium alginate, with a cationic drug molecule in an aqueous 
environment, and to apply this knowledge to provide a rational 
approach to the deSign of a controlled release drug delivery system 
based on drug:polysacchartde complexes. 
To date. the interaction of ionic polysacchartdes with drug 
molecules has been viewed as a disadvantage, for example, it has 
been reported that cationic antiseptics, including aCriflavine 
chlOride and cetylpyridinium chlOride become inactivated in 10/0 
ammonium alginate gel as a result of complex fonnation (Ketpert et 
al 1973). There have been few studies which have investigated the 
potential of using such interactions for controlling drug delivery. 
even though the control of drug release is desirable in many routes 
of administration (for example, the nasal route) in order to prevent 
peaks and troughs in blood plasma levels. The nasal route in the rat 
was chosen as a suitable animal model in which to test this system. 
since many drugs are readily absorbed from the nasal cavity, but with 
some, absorption occurs so rapidly that the resulting high blood 
level peaks may give rise to Side-effects. The model drug 
propranolol hydrochloride is rapidly absorbed intranasally, therefore 
control of drug release is required to retard absorption of drug and 
to flatten the blood level peaks. 
Polymers are routinely included in nasal liquid fonnulations 
to prolong nasal retention time by increasing viSCOSity. and some 
ionic polysaccharides appear to slow the release of certain nasally 
administered drugs over and above that seen from a viscosity effect 
alone. It was therefore deCided to investigate the interaction of an 
ionic polysaccharide, sodium alginate. with a model cationiC drug. 
propranolol hydrochlOride, with a view to designing a controlled 
release drug delivery system. 
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In these studies. two highly purified alginates from Laminaria 
hyperborea and AscophyUum nodosum were first characterised in 
terms of molecular weight. polydispersity and M:G ratio. prior to 
drug binding studies to investigate their interaction with 
propranolol hydrochloride. The Laminaria hyperborea alginate was 
found to have a higher proportion of G-blocks (M:G ratio = 35:65) 
than the Ascophyllum nodosum alginate (M:G ratio = 61:39). 
Preliminary investigations on the interaction between sodiuln 
alginate and propranolol using viscometry and nephelometry 
provided evidence that. above certain concentrations, there was an 
interaction between propranolol and sodium alginate in deionised 
water resulting in the formation of a precipitate. Furthennore. it was 
found that the addition of sufficient counter-ions, for example 
sodium chloride ions. could re-dissolve the precipitate. suggesting 
that the interaction was ionic in nature. possibly as a result of 
ion-pairing between the positively-charged propranolol and the 
negatively-charged alginate. 
In order to quantify this interaction in the presence and 
absence of sodium chlOride. an equilibrium dialysis technique was 
used. The results from the dialysis studies again suggested that the 
interaction between alginate and propranolol was ionic in nature and 
that at the saturation pOint. stoichiometric 'one-to-one' binding was 
occurring. with one propranolol molecule interacting with one 
carboxyl group on each hexose residue of the alginate chain. No 
difference in the degree of binding of propranolol to the high -G or 
high-M alginate was observed. This was unexpected. since it has 
been found by other workers that with. for example, calcium ions. 
the interaction is much stronger with high-G alginates and results in 
the formation of strong brittle gels compared with the much weaker 
gels formed with high-M alginates. Examination of the binding 
isotherms indicated that 'negative co-operativity' was occurring, so 
that the binding of one propranolol molecule to a carboxyl group on 
the alginate made it more difficult for other propranolol nlolecules 
to bind to adjacent carboxyl groups. The use of molecular Inodelling 
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to visualise the possible in-vacuo three-dimensional structure of the 
ionic complex formed between propranolol and alginate supported 
this finding, in that it showed that the presence of one propranolol 
molecule binding to the alginate could make it stereochem1cally 
difficult for subsequent molecules to bind. 
In order to prepare a dosage form which could be 
conveniently reconstituted for administration in vivo, a freeze-dried 
alginate/propranolol complex was prepared. This was suspended in 
either deionised water or in isotonic glycerol solution and tested in 
vitro for release of propranolol across a semi-permeable membrane 
into sodium chloride solution. It was found that release of 
propranolol from the complex in suspension was delayed cOlnpared 
with release from a propranolol solution. It is postulated that the 
reason for this delay is that. whereas the release profile for 
propranolol solution is dependent only on the rate of diffusion 
across the semi-permeable membrane. several processes occur in 
order for propranolol to be released from the complex. That is. 
sodium ions diffuse in and. since the affinity of the sodium ions for 
the alginate is greater than that of the propranolol ions. ion 
exchange occurs releasing drug and dissolving the propranolol/ 
alginate complex. Propranolol ions then diffuse across the 
membrane into the sodium chloride solution. 
The release of propranolol from the formulations previously 
tested in vitro was then assessed in vivo. Nasal delivery in the rat 
was chosen as a model in vivo system in which to investigate the 
potential of alginate ionic complexes to control drug absorption. It 
was found that the nasal delivery to rats of a propranolol/ alginate 
complex in suspension resulted in a significant reduction in the rate 
of drug absorption compared to a solution formulation, but that the 
bioavailability remained unchanged and comparable to that of an IV 
dose carried out in rats by other workers (Hussain et al 1980b). The 
sustained release observed in vivo was much greater than would have 
been predicted from the in vitro results. However, this may be due 
to several factors. For example. there is a limited amount of fluid 
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present in the nose of the rat compared to the almost 'sink' 
conditions employed in the in vitro experiments. In addition. mucus 
in the nose could act as a barrier to the in vivo absorption of 
propranolol. Lastly, although the presence of cations such as Ca2+ in 
the mucus could displace propranolol from the complex. they could 
also cause the alginate to gel, thereby delaying propranolol 
absorption since it would have to first diffuse through the polymer 
gel network. 
The work in this thesis has focussed on the interaction and 
complexation of one ionic polysaccharide with a model drug. The 
results have demonstrated that. in vivo via the nasal route. this 
complexation results in more sustained release rates from the 
complex than from a drug solution alone. without affecting the 
bioavailability of the drug. It is possible that these results may be 
applicable to a variety of other naturally occurring or synthetic 
polysaccharides combined with drugs which have applications for 
nasal delivery (either for their local or their systemic effects). In 
addition, the complexation of drugs with polysaccharides may have 
potential as delivery systems for many other routes. for example. the 
oral, vaginal rectal and ocular routes. or in wound dressings and 
dental pastes. 
The future success of nasal delivery systems for humans 
depends on their being commerCially viable compared to. for 
example. parenteral or oral administration. Therefore. future work 
should include systematic investigations into the interaction of a 
range of polysaccharides with various drugs in order to manipulate 
the physicochemical properties (and thereby the absorption 
characteristics) of the drug molecules. Such investigations may allow 
the development of novel delivery systems which in the future could 
prove to have important consequences for the delivery of a variety of 
drugs. for example insulin for diabetic patients. which at present 
can only be administered via the parenteral route. Who nose? 
-169-
APPENDIX 1 
Calculation of the Composition and Sequence Paranleters froIll the 
NMR Spectra of L. hyperborea and A. nodoswn a l ~ i n a t e s . .
The follOwing equations apply to the NMR spectra shown in figures 
2.9 and 2.10 (I is the area under the peaks): 
FGG = FGGG + FGGM 
Itotal = IG + IMM + IMG 
( where IMG = (IMG + IMGG + IMGM)/2 ) 
FG = IG/ltotal 
FGG = IGG/ltotal 
FMG,GM = FG - FGG 
FMM = FM - FGM,MG 
FGGG = IGGG/ltotal 
FGGM = FGG - FOGG 
FMGM = FGM - FGGM 
NG (average length of G-blocksl = FG/FMG 
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til Laminaria hyperborea alWlate 
Itotal = 1144 + 401 + (213 + 90 + 146)/2 = 1769.5 
FG = 1144/1769.5 = 0.647 
FM = 1 - 0.647 = 0.353 
FGG = (832 + 129)/1769.5 = 0.543 
FMG,GM = 0.647 - 0.543 = 0.104 
FMM = 0.353 - 0.104 = 0.249 
FGGG = 832/1769.5 = 0.470 
FGGM = 0.543 - 0.470 = 0.073 
FMGM = 0.104 - 0.073 = 0.031 
NG = 0.647/0.104 = 2:2 
(iil Ascophyllum nodosum alflinate 
Itotal = 527 + 547 + (245 +95 + 221)/2 = 1354.5 
FG = 527/1354.5 = 0.389 
FM = 1 - 0.389 = 0.611 
FGG = (228 + 89)/1345.5 = 0.234 
FMG,GM = 0.389 - 0.234 = 0.155 
FMM = 0.611 - 0.155 = 0.456 
FGGG = 228/1354.5 = 0.168 
FGGM = 0.234 - 0.168 = 0.066 
FMGM = 0.155 - 0.066 = 0.089 
NG = 0.389/0.155 = 2& 
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APPENDIX 2 
P r O ~ a m m to Calculate Area under the 
Plasma/Time Curve (AUCl 
1 REM •••••••••••••••••••••••••••••••••••••• ~ ~ •••• * ••• 
2 REM 
3 REM 
4 REM 
INTEGRAL 
5 REM ••••••••••••••••••••••••••••••••••••••••••••••• 
10 REM •••••••••••••••••••••••••••••••••••••••••••••• 
20 REM This program calculates the area under a curve 
30 REM of a set of data pOints 
40 REM An extraplolation to zero is then carried out 
45 REM using a least square fit procedure 
50 REM to find the area under the tail 
60 REM Dr P J Kirk 
65 REM Department ot Physics, University of Nottingham 
70 REM 
80 REM •••••••••••••••••••••••••••••••••••••••••••••• 
100 REM The variable XCI) represents the TIME variable 
110 REM The variable Y(I) represents the concentration 
120 REM of propranolol at time t 
200 REM ••••••• Input data •• •••••••••••••••••••••••• 
210 DIM X(100),Y(100) 
220 CLS 
230 WRITE 
240 INPUT "Please input the number of data points(5-100)":NP 
243 IF (NP<5) OR (NP>100) THEN P R I ~ T T "TRY AGAIN" :GOTO 240 
245 PRINT "Please input the data points in ascending values of x" 
250 FOR I = 1 TO NP 
255 PRINT "Data point ":1 
260 INPUT "Please input the TIME (in minutes)":X(I) 
270 INPUT" the Prop CONC":Y(I) 
280 NEXT I 
290 GOSUB 1000 
300 REM •••••••••••• 
310 REM ••••••• •••••• 315 FOR I = 1 TO NP 
320 XSUM = 01 
321 YSUM =01 
325 N = 4 
work out linear regression on last tive points··· 
convert XCI) into hours •••••••••••• 
: XCI) = X(I)/60:NEXT I 
330 FOR I = (NP-N+l) TO NP 
340 XSUM = XSUM + XCI) 
350 YSUM = YSUM" +Y(I) 
360 NEXT I 
370 XMEAN = 
380 YMEAN = 
390 REM ••• 
400 H = 0 
410 FOR I = 
420 H = H + 
430 D = D + 
435 NEXT I 
440 A = HID 
XSUM/N 
YSUH/N Find the best tit gradient (A) and best tit intercept (B)·· 
D = 0 :A =0 
(NP-N +1) TO NP 
( Y(I)·CX(I)-XMEAN» 
« X ( I ) - ~ H E A N ) A 2 ) )
450 B = YMEAN - A·XHEAN 
480 H=O 
470 FOR I = (NP-N +1) TO NP 
480 H = H + «Y(I)-A·X(I)-B)A2) 
490 NEXT I 
500 DA = H I( (N-2)·D) 
505 DA = SQR(DA) 
510 DB = ( (liN) + ( (XMEAN A2)/D»·(M/(N-2» 
515 DB = SQR(DB) •••••••••• 520 REH •••••••• end ot regression ••••••• 
530 REM ••••• tind x axis intercept ••••••• ~ ~ -
535 IF (A =0) THEN PRINT- REGRESSION H O R I Z O ~ T A L L : E ~ D D
540 X(NP+l) = -B/A 
550 Y(NP+l) .0 
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600 R E ~ ~ *** Calcuiate area under the curve *.*** ••••••• 
605 R E ~ ~ .*. using the trapeZium rule .* •••••••••••••••• 
610 AREAL = O! 
620 AREA2=01 
630 FOR I = 1 TO ~ P - 1 1
6 ~ 0 0 AREAL = AREAL + ( X(I+l) -X(I».(Y(I+l) +Y(I»/2 
650 NEXT I 
660 AREA2 = AREAL + ( X ( N P + l ) - X ( ~ P » . ( Y ( ~ P + l ) + Y ( N P » / 2 2
670 DELA = ABS«AREA2-AREA1)*( (DB/B) + (DA/A») 
700 R E ~ ~ ****.*** Print results ••• * ••••••• * ••• * •••••••• 
710 CLS 
720 FOR I = 1 TO 5 : P R I ~ T T • • : NEXT I 
730 PRINT· The minimum area without extrapolation = - :AREAl 
740 PRINT 
750 P R I ~ T T . 
755 PRINT " 
756 FOR I = 1 TO 
760 PRINT ,. R 
765 PRINT ,. M 
775 PRINT ,. E 
The area With Linear extrapolation = ":AREA2 
The error = +/-";DELA 
3 : P R I ~ T " - : N E X T T I 
Run Integral With a New Set Of Data" 
Modify Data and Re - Run Integral" 
End .. 
THEN GOTO 780 
OR ASC(BS) = 
OR ASC(BS) = 
OR ASC(BS) = 
1 1 ~ } T H E N N GO TO 10 
109)THEN GOSUB 1000:GOTO 300 
101)THEN GOTO 999 
780 BS = INKEY$ 
790 IF LEN(BS) = 0 
800 IF (ASC(BS)=82 
820 IF (ASC(BS)=77 
830 IF (ASC(BS)=69 
999 END 
1000 REM •• ** ••• This subroutine checks the data and allows •••••••• 
1001 REM *.*** •• changes to the data before integration •••••••••••• 
1010 CLS 
1020 PRINT" • 
1030 PRINT "·,"I".-Time(mins)",·Conc" 
1040 PRINT 
1050 FOR I = 1 TO NP 
1060 PRINT "",I.XCI),Y(I) 
1070 NEXT I 
1075 PRIST· Do you wish to change any data?(Y/N)· 
1080 AS = INKEYS 
1085 IF LENCAS) = 0 THEN 1080 
1090 IF (ASC(AS) =110 OR ASC(AS) = 78 ) THEN GOTO 1200 
1100 IF (ASC(AS) = 121 OR ASC(AS) = 89 ) THEN GOTO 1120 
1110 GOTO 1080 1120 INPUT" Please input number of data set you wish to change";C 
1130 PRINT "" 
1140 INPUT "Please input the new TIME ";X(C) 
1150 INPUT" new CONC ";Y(C) 
1160 GOTO 1010 
1200 RETURN 
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